



Published in final edited form as:

J Med Chem. 2011 May 26; 54(10): 3524–3548. doi:10.1021/jm2001053.

Development of Amidine-Based Sphingosine Kinase 1 Nanomolar Inhibitors and Reduction of Sphingosine 1-Phosphate in Human Leukemia Cells

Andrew J. Kennedy^{*,1}, Thomas P. Mathews^{1,2}, Yugesh Kharel², Sandra D. Field¹, Morgan L. Moyer¹, James E. East¹, Joseph D. Houck¹, Kevin R. Lynch², and Timothy L. Macdonald^{1,2}

¹ University of Virginia Department of Chemistry, McCormick Road, Charlottesville, VA 22904

² University of Virginia Department of Pharmacology, 1340 Jefferson Park Avenue, Charlottesville, VA 22908

Abstract

Sphingosine 1-phosphate (S1P) is a bioactive lipid that has been identified as an accelerant of cancer progression. The sphingosine kinases (SphKs) are the sole producers of S1P and thus SphK inhibitors may prove effective in cancer mitigation and chemosensitization. Of the two SphKs, SphK1 overexpression has been observed in a myriad of cancer cell lines and tissues, and has been recognized as the presumptive target over that of the poorly characterized SphK2. Herein, we present the design and synthesis of amidine-based nanomolar SphK1 subtype-selective inhibitors. A homology model of SphK1, trained with this library of amidine inhibitors, was then used to predict the activity of additional, more potent, inhibitors. Lastly, select amidine inhibitors were validated in human leukemia U937 cells, where they significantly reduced endogenous S1P levels at nanomolar concentrations.

Introduction

The scientific community has identified the sphingosine kinases (SphKs) as potential therapeutic targets for broad cancer mitigation and chemotherapeutic sensitization.^{1, 2} The SphKs are the sole producers of sphingosine 1-phosphate (S1P), which regulates cell survival, proliferation, neovascularization, and migration through five G protein coupled receptors (S1PR₁₋₅) as well as through other intracellular mechanisms.³⁻⁷ Upregulation of the SphK1, the first of two SphK isoforms, is found in many cancers (brain,^{8, 9} bladder,¹⁰ breast,^{11, 12} colon,^{13, 14} gastric,¹⁵ head and neck,^{16, 17} leukemia,¹⁸ non-Hodgkin lymphoma,¹⁹ prostate,^{20, 21} skin,²² and squamous cell carcinoma;²³ among others) and the overproduction of S1P has been shown to aid angiogenesis, tumorigenesis, and metastasis.

Because of its deregulation in cancer, SphK1 has been implicated as a potential oncogene;^{2, 24} however, no genetic mutations have yet been identified, indicating that malignancies may become dependant on SphK1 through a non-oncogene addiction.²⁵ This theory is appealing due to the central role that S1P plays in the signal amplification of other known oncogenes. SphK1 expression and activation increases with mitogenic signaling from

*Corresponding Author. Tel: 434-924-0595. Fax: 434-982-2302. ajk3p@virginia.edu. Mail: University of Virginia, Department of Chemistry PO Box 400319, McCormick Road, Charlottesville, VA 22904.

Supporting Information Available: Includes the synthetic schemes for compounds **30** and **47**, the tabulated results form the inhibitor docking studies, and the SphK1/DGKB sequence alignment. This material is available free of charge via the Internet at <http://pubs.acs.org>.

growth factors for a range of receptor tyrosine kinases²⁶ (epidermal (EGF), vascular endothelial (VEGF), platelet derived (PDGF); among others), estrogen signaling,²⁷ prolactin expression,²⁸ and lysophosphatidic acid (LPA) signaling,²⁹ which indicates SphK1 inhibitors may be capable of counteracting a range of oncogene-accelerated cancers. SphK1 expression has also been shown to protect rapidly dividing cells from hypoxia,³⁰ autophagy,³¹ and chemotherapy.³² SphK1 siRNA has been shown to slow the rate of growth of cancer cells that have SphK1 overexpression.^{20, 21, 32, 33} Breast cancer,¹² gastric cancer,¹⁵ and glioblastoma^{8, 9} patients with high levels of SphK1 have shorter life expectancies. The relationship between SphK1 and cell survival can be described as linear; with increased S1P facilitating more aggressive and chemotherapeutic resistant cells, and decreased S1P leading to a build up of ceramide, its biosynthetic precursor, and ceramide dependant apoptosis.³⁴ Indeed, the sphingosine rheostat (Scheme 1) that governs cell fate by controlling the ratio of S1P to ceramide could be manipulated by applying the correct resistance at SphK1 with small molecule inhibitors that “dial-down” S1P concentrations.

To state that the less-inducible SphK2 is simply the housekeeping isoenzyme of SphK1 would be misleading. Unlike SphK1, which is cytosolic and when phosphorylated translocates to the inner leaflet of the cell membrane,³⁵ SphK2 is predominately located on or in the organelles, such as the ER or the nucleus.³⁶ Due to this location, S1P produced by SphK2 in the interior of the cell is not effectively positioned to enter into the inside-out S1P receptor signaling pathway occurring at the cell membrane, and therefore does not have the same proliferative effects.³⁷ Instead, S1P synthesized in the nucleus by SphK2 causes histone deacetylase 1 and 2 (HDAC 1/2) inhibition, p21 gene expression, and cytostasis.⁷ SphK2 overexpression causes apoptosis, which is most likely due to its degradation by the proteasome and release of a short pro-apoptotic BH3-domain present in SphK2 that is absent in SphK1.³⁸ The relationship between SphK2 and cell survival appears to be parabolic; where upregulation leads to its degradation and caspase-mediated apoptosis, moderate activity leads to p21 expression and cell cycle arrest, and downregulation leads to reduced p21 expression and apoptosis or proliferation depending on cell environment.¹

If SphK inhibitors are to be used to mitigate the presentation of cancer or, to retard chemotherapeutic resistance, the question must be raised: Is it necessary to selectively inhibit one of the SphKs or inhibit both enzymes together? The inducibility of SphK1 by mitogenic factors is an indication of disease causing deregulation, however, siRNA experiments demonstrate that “knocking-down” SphK2 is more efficacious at retarding cell growth in two glioblastoma cell lines.⁹ It is possible that the inhibitor subtype selectivity necessary for effective treatment may be cancer dependent, and our research aim is to synthesize a spectrum of dual and selective SphK inhibitors.

Over the last few years several SphK inhibitors have appeared in the literature.¹ A large portion of these are amino alcohol sphingosine analogs that compete for the substrate binding pocket,^{39–44} however, the ATP competitive SKI-II is one notable exception.⁴⁵ Indeed, sphingosine kinase inhibitors with μM K_i values have been effective *in vivo* in suppressing tumor growth in xenograft models^{39, 41, 46} and inhibited inflammation response in Crohn's,⁴⁷ inflammatory bowel,⁴⁸ and sepsis⁴⁹ disease models. However, there is still a need for a library of potent SphK inhibitors with a range of subtype selectivities that could elucidate the currently enigmatic differences between the SphKs in cancer disease states.

Previous work has led to the generation of sub- μM dual and selective SphK inhibitors **1** and **2**, which were derivatives of the initial hit compound (*S*)-*N*-(1-amino-1-iminopropan-2-yl)-4-octylbenzamide hydrochloride (**VPC94075**) (Table 1).⁵⁰ These amidine-based lipids were selective for the SphKs; they did not inhibit other lipid kinases, such as the diacylglycerol kinases (DGKs), or protein kinases, such as protein kinase C (PKC). They

were, in our opinion, excellent starting points for drug optimization. The most interesting feature of the preliminary SAR was the selectivity for SphK1 induced simply by the direction of the amide functional group present in compounds **1** and **2**. The amide-controlled selectivity was dependent on tail length, with a maximum effect only observed in the longer tailed derivatives. Potency and selectivity are affected by tail length and amide configuration as described in Figure 1. Shorter tails (C8 and C10) inhibit both SphK1 and SphK2 equally, but the maximum potency tail length of C12 differentiates dual inhibition and SphK1 selectivity based on amide direction before potencies drop off at longer tail lengths.

These differences can be explained by the tail-binding region of the substrate pocket of SphK1 being larger than that of SphK2, which forces an altered binding position for the inhibitors and causes a repulsive electrostatic interaction for the amide configuration in compound **2**. Seeking to exploit this tail length and amide derived selectivity; inhibitors with increased terminal steric bulk and amide rigid analogs derived from proline were synthesized and tested. Scheme 2 shows the individual head and tail optimizations and subsequent partnership to generate compound **38**, which has a $K_I = 75$ nM at SphK1 and is 80-fold selective over SphK2. The library of inhibitors synthesized was then used as a test set in the generation of a SphK1 homology model derived from the solved structure of diacylglycerol kinase β (DGKB).⁵¹ Lastly, a virtual library of possible linkers was docked into the SphK1 model and a class of heteroaromatic compounds with six fewer rotatable bonds was generated and synthesized. Biochemical evaluation led to the identification of the most potent inhibitors of SphK1 reported in the literature to date.⁵² Oxazole **56**, which has a $K_I = 47$ nM at SphK1 and 180-fold selectivity, and other amidine-based inhibitors described are shown to significantly reduce SIP concentrations in human leukemia U937 cells at nanomolar concentrations.

Results and Discussion

Tail Modifications

The tail region was defined to be everything distal to the amidine beyond the amide bond (Scheme 2). Three major modifications were made to the scaffold of compound **2**: aryl deletion, the substitution of terminal ethers, and the substitution of terminal aromatics. The aryl deletion series was synthesized in two steps from the commercially available starting aliphatic amines and 1-cyano-1-cyclopropane. In the example shown in Scheme 3, tetradecylamine was coupled using PyBOP to form the nitrile **3a**, and then transformed under base catalyzed Pinner conditions⁵³ to yield the corresponding amidine **4a**.

The ether tail derivatives were then examined and terminal steric bulk was built into the ether from the corresponding alcohol. In the example synthesis shown in Scheme 4, benzyl alcohol was coupled to 7-bromo-1-heptene using sodium hydride in DMF to form ether **5a**. The terminal olefin was reduced to an alkylborane *in situ* using 9-BBN and then introduced to Suzuki conditions to be coupled with 1-bromo-4-nitrobenzene to form the aryl nitro **6a**. On reduction to the aniline **7a** with zinc dust and amide coupling facilitated by PyBOP to form nitrile **8a**, our standard amidine formation lead to the final product **9a**.

The non-ether aromatic tails were synthesized to compare the solubility effects of introducing an ether linkage in the middle of the tail region. In the example synthesis shown in Scheme 5, benzylmagnesium bromide was catalytically converted to its organocuprate with cuprous chloride, and coupled to 8-bromo-1-octene to form alkene **8a**. This olefin was identical to that of compound **5a**, with the exception of the ether linkage being substituted with a methylene, and was converted to its corresponding final product under similar chemical transformations.

The K_I values of these tail derivatives were determined by a [γ - 32 P] ATP *in vitro* assay⁵² of SphK enzymatic activity and are shown in Table 2. The most striking observation about the aryl deletion series **4a-c** was the lack of a potency response to changes in tail length. Unlike the aryl-containing analogs described in Figure 1, these saturated tails had a flat SAR in the low μ M range, but did maintain SphK1 selectivity in the longer tailed **4b** and **4c**. It was hypothesized that these more hydrophobic compounds had strong affinities for the active site, but were so water insoluble that their active concentrations were small due to aggregation. The more soluble ether tails performed with a more consistent SAR, with the smaller terminal phenyl-containing **9a** being less active than the cyclohexyl **9c** by more than a log order (Table 2). The terminal cyclohexyl derivative **9c** was synthesized to evaluate saturation as compared to the aromaticity of **9a**, and the positive performance of **9c** suggests a preference for the larger and more hydrophobic terminal cyclohexane. Adding further steric bulk in the adamantyl derivative **9e** caused a loss of activity and selectivity, suggesting an alternative binding conformation for such a large substituent. Short and longer cyclohexyl-containing tails, **9b** and **9d** respectively, both performed more poorly than **9c** indicating that it was the optimum length.

Unfortunately, compound **9c** did not yield the substantial gains in potency or selectivity that were expected, but did increase water solubility to a CLogP = 3.61 versus a CLogP = 4.00 for compound **2**.⁵⁴ This added polar character allowed us to reconsider the aryl deletion series, and compounds **19a** and **19b** were then synthesized. Shown in Scheme 6 is the example synthesis of **19a**; cyclohexylmethanol was coupled to 10-bromo-1-decene using sodium hydride in DMF to form ether **15a**. The terminal olefin was converted to the primary alcohol **16a** under hydroboration/oxidation conditions, and then displaced to the primary azide **17a** through its mesylate. The azide **17a** was reduced and ligated using Staudinger conditions⁵⁵ to form nitrile **18a**, before being converted to amidine **19a**. Compound **19a** proved to be both more potent, with a K_I = 110 nM, and 470-fold selective for SphK1 over SphK2. The reduction in terminal ring size to the cyclopentyl **19b** demonstrated that the steric bulk of the 6 membered saturated ring of **19a** was optimal for both potency and selectivity (Table 2).

Having achieved the design of a compound two and one half log orders selective for SphK1, our attention shifted to whether the bulkier tail design had aided selectivity in an amide-dependant manner. To test this relationship, the inverted amide derivatives of compounds **9c** and **19a** were synthesized. The synthesis of the aryl containing inverted amide is shown in Scheme 7; starting from the same terminal alkene used in the synthesis of **9c**, the reduction of **5c** to its alkylborane and coupling under Suzuki conditions to 4-bromobenzaldehyde gave the aryl aldehyde **20a**. The aldehyde was then oxidized to benzoic acid **21a** using Pinnick oxidation conditions.⁵⁶ The carboxylic acid was coupled to 1-amino-1-cyclopropanecarbonitrile through its acid chloride. Nitrile **22a** was then converted to its amidine to form the desired **23a**. The synthesis of the non-aryl inverted amide analog **26** was relatively simple, starting with the Williamson ether coupling of cyclohexylmethanol and 11-bromoundecenoic acid (Scheme 8). The acid **24** was then coupled to 1-amino-1-cyclopropanecarbonitrile with PyBOP to form nitrile **25**, and converted to the corresponding amidine **26**.

The results from the amide inversion experiments demonstrated that a cyclohexane at the tail terminus does itself increase selectivity for SphK1, as shown in the differences in activity between compounds **1** and **23a** (Table 3). Again, substitution to the smaller cyclopentane reduced activity and selectivity. It was expected that a direct ether substitution in the tail of compound **1** would lead to reduced activity against both kinases equally due to its increased solubility in water; however, compound **23c** lost potency disproportionately leading to a slight degree of SphK1 selectivity. The selectivity was due to the position of the ether

linkage along the tail, and compound **30** was synthesized (Scheme SI-1) and evaluated to show no such change in selectivity compared to the saturated parent compound **1**.

An important subtlety of the tail modification data is that the deletion of the aromatic ring present in **9c**, and replacement with a three carbon saturated spacer as in **19a** increased both potency and selectivity (Table 2). However, the same conversion from **23a** to **26**, increased potency without such an obvious effect on selectivity. One explanation is that a saturated amide increases potency and accentuates the effect that amide already has on selectivity. On the other hand, a bulky substitution at the tail terminus, such as a cyclohexane, increases potency and selectivity regardless of amide orientation.

Head Group Modifications

An early examination of substitution alpha to the amidine showed that small substituents, such as methyl and cyclopropyl, were tolerated well by the enzyme.⁵⁰ It was therefore desirable to test a bulkier cyclobutyl derivative, however, a ring expansion to the cyclobutyl would affect the angle of presentation of the amidine possibly hindering its function. More promising was a rigid analog design that restricted the dihedral angle between the position of the amide and that of the amidine. Restricting a bond between such functionally important groups should have an effect on selectivity and potency. Derivatives of both enantiomers of proline provided a synthetically useful avenue to rigidity, and would allow freedom of rotation about the amidine while restricting rotation of the amide.

The synthesis of the alpha, alpha-cyclobutyl analog **33** began with the conversion of cyclobutanone under Strecker conditions to 1-amino-1-cyclobutanecarbonitrile **31** (Scheme 9). Immediate acylation with 4-dodecylbenzoyl chloride to form nitrile **32**, and conversion to its amidine gave compound **33**. Next, the proline-based rigid analog syntheses began from the corresponding asymmetric amino acid (Scheme 10). L-proline was first N-Boc protected, before converting its carboxylic acid to the primary amide, and lastly dehydration of that amide to the nitrile in compound **34a**. The Boc group was then deprotected and the free amine coupled using PyBOP to 4-dodecylbenzoic acid to form compound **35a**. The nitrile was then converted to its amidine, and the synthesis was repeated for D-proline to produce both enantiomers.

Table 4 shows the biological evaluation of the head group analogs. As suspected, the ring expansion from cyclopropane to the cyclobutane present in **33** worsened activity equally against both SphKs. The proline analogs **36a,b** yielded selectivity as expected, with the (S) configuration derived from L-proline being 24-fold more selective for SphK1 while the (R) enantiomer was slightly SphK2 selective with less potency.

Compound **36a** being more potent and selective for SphK1 than compound **1**, a synthesis combining our best tail derivatives with a (S) proline head group was undertaken (Scheme 11). The aryl **38** and non-aryl **40** were synthesized and evaluated to have K_I values of 75 nM and 130 nM respectively (Table 4). In previous series it was noted an increase in activity for the non-aryl over the aryl amide substitution (Tables 2 and 3). However, that relationship was for mono-nitrogen substitution on the amide bonds, while the proline derivatives are di-nitrogen substituted. For the proline aryl amides, A^{1,3} strain prohibits bond rotation about the carbonyl carbon aryl bond, effectively rigidifying two bonds as compared with compound **23a**. The saturated **40**, which is mono-substituted alpha to the carbonyl, has the ability to freely rotate, and has only one rigidified bond as compared with compound **26**. The potency of the proline analogs is therefore dependent on a substitution alpha to the amide carbonyl that inhibits bond rotation, which prepays the cost of freezing that bond prior to reaching the enzyme active site.

The ether present in the tail increases its calculated water solubility, and in the case of **23c** reduces activity versus its non-ether counterpart **1**. A synthesis was then undertaken to eliminate the ether from compound **38** to investigate the limit of such solubility dependence. The synthesis of the non-ether **47** was completed (Scheme SI-2), and it was determined that its lower water solubility caused a decrease in activity (Table 4). The loss of activity for **47** and other compounds with high Clog P values suggests an ideal Clog P around 4.2.

***In Silico* Linker Screening**

Crystal structures of kinases that bear close sequence homology to the ATP binding domain of the SphKs have been solved for YegS,^{57, 58} a bacterial lipid kinase, phosphofructokinase (PFK),^{59, 60} and DGKB.⁵¹ Of these structures, DGKB has the greatest overall sequence identity of 20% to SphK1. Cases of such low sequence identity are often referred to as “twilight zone” cases,⁶¹ and a 28 amino acid sequence that defines the substrate binding pocket of SphK1 has no meaningful sequence homology. It should be stated that modelers tread lightly in such situations, and any conclusions drawn should be supported by experimental data. However, the sequence homology between the two kinases suggests that SphK1 shares the basic quaternary structure of a beta-sandwich in DGKB, connected to the ATP binding domain through a hinge.

A homology model of SphK1 was generated (see supporting information for details pertaining to model generation and inhibitor docking) from the solved crystal structure of DGKB⁵¹ (Figure 2a). The current library of amidine inhibitors was docked into the SphK1 model (Figure 2b), and illuminated an interesting hypothesis of how the amidine may interact with the enzyme. The model suggests that the amidine interacts directly with ATP through a bidentate chelation of its gamma phosphate (Figure 2c and 2d). This supports a mechanism of inhibition where SphK first binds ATP and the inhibitor, and the amidine acts to stabilize the [SphK • ATP • I] complex. Using the test set of known amidine-based inhibitors enabled the virtual screening of theoretical amidine inhibitors and a prediction of their enzymatic activity.

Long unrestricted alkyl chains have a large number of rotatable bonds, which add a large entropic cost when forced to lock into a single binding conformation. Our most potent compounds have between 11 and 15 rotatable bonds, thus it was desirable to reduce these large degrees of freedom by incorporating linker regions that are comprised of as many ring structures as possible. The SphK1 model suggests a tail binding region that is mostly comprised of hydrophobic surface area, indicating that this region of the pocket simply acts as a hydrocarbon ruler designed for sphingosine recognition. Therefore, without much possibility of polar interaction the ideal tail would be one that maximizes the energy associated with ligand and pocket desolvation. Assuming the binding positions of the amidine head group and the cyclohexyl tail fragments were accurate, several hundred possible linkers were created *in silico*, docked into the SphK1 homology model, and scored (see supporting information). These potential linker regions consisted of substituted benzenes, heteroaromatics, saturated rings, fused rings, and alkyl spacers in varying order, and scaffolds were chosen for both their predicted potencies as well as ease of synthesis. Figure 3 shows the general scaffold picked as a proof of principle for the linker region generation. It is a proline-based rigid analog series that includes a five-membered heterocycle with an aryl-aryl bond to another benzene that is meta substituted by a two carbon spacer to the terminal cyclohexane. The presence of a centralized heterocycle was ideal for solubility manipulation, and the synthesis of the X/Z imidazole, oxazole, and thiazole was undertaken to demonstrate a solubility/activity relationship. Figure 4 illustrates the linker generation process where the docking conformation of compound **38** (Figure 4a) was fragmented into an aryl amide head group and a cyclohexyl tail terminus (Figure 4b),

and the *in silico* linker screening procedure led to a theoretical aromatic tail derivative (Figure 4c).

The synthesis of imidazole **53** began with the hydroboration of vinylcyclohexane and subsequent Suzuki coupling with 3-bromoacetophenone to form ketone **48** (Scheme 12). The ketone was then alpha brominated with molecular bromine and displaced by the cesium salt of mono tert-butyl protected terephthalic acid to yield ester **50**. Compound **50** was then cyclized in refluxing xylenes with ammonium acetate to produce imidazole **51**, which was deprotected and coupled to form nitrile **52**. Standard Pinner conditions then yielded the desired imidazole containing amidine **53**. The synthesis of oxazole **56** diverges from that of the imidazole at compound **50**, which is cyclized in AcOH with ammonium acetate to yield the acid deprotected oxazole **54** in one step (Scheme 13). Amide followed by amidine formation then produced the oxazole containing amidine **56**. Synthesis of the thiazole required the conversion of the mono tert-butyl protected terephthalic acid to its terminal amide using isobutylchloroformate and ammonia in methanol (Scheme 14). This terminal amide could then be transformed into the thioamide **57** using Lawesson's reagent. Thioamide **57** was smoothly coupled then cyclized with the alpha bromoketone **49** to yield the thioazole **58**. Tert-butyl deprotection, amide formation, and then amidine synthesis produced the desired thioazole containing amidine **60**.

The SphK1 model predicted and *in vitro* determined K_I values for the heterocycle series are listed in Table 5. All three heterocycles were predicted to geometrically fit in the substrate pocket, but the SphK1 model predicted a "Goldilocks" effect based on solubility, where the oxazole **56** with a Clog P of 4.24 should have the lowest K_I value of 30 nM. The imidazole **53** and the thiazole **60** were predicted to have lesser potencies due to being too polar and hydrophobic respectively. On biological evaluation the model performed quite well, yielding the correct order of potency and predicting the actual K_I value (47 nM) of the oxazole **56** within the 95% confidence limits. Indeed, the imidazole was the only compound of the three that had an experimentally determined K_I value outside the 95% confidence limit, and this is probably due to the ratio of protonated versus neutral states. The pKa of the protonated imidazole ring is predicted to be around 7 in water, and if one assumes that the charged species has a $K_I > 10 \mu\text{M}$, then that ratio would proportionally reduce the activity of compound **53**. Comparing Clog P to reverse-phase HPLC retention time, which is a standard measure for comparing relative water solubilities, validates this reasoning (Figure SI-3). The retention times of the presented library of amidine containing inhibitors correlates well with Clog P ($R^2 = 0.71$), and compound **53** is an outlier of this trend (see supporting information).

***In Vitro* Evaluation of Inhibitors in U937 Cells**

To evaluate how well these amidine-based inhibitors penetrate and reduce endogenous S1P levels in living cells, U937 cells were pretreated with compounds **1**, **19a**, **38**, and **56** for 2 hours (Table 6 and Figure 5). U937 cells are a human monoblastic leukemia cell line, whose S1P levels have been reduced by micromolar concentrations of the known sphingosine kinase inhibitor dimethyl sphingosine (DMS).^{40, 42} The amidine-based inhibitors indeed showed inhibition at concentrations near the K_I values, all showed significant S1P reduction at 100 nM. At 10 nM concentrations, lower than the K_I values of all the inhibitors, S1P reduction was still observed for compounds **19a** and **38**. In other experiments (not shown), it was determined that the decreased accumulation of S1P in U937 cells was the result of blockade of synthesis, rather than increased decay or export of S1P.

To compare these amidine based inhibitors to other known sphingosine kinase inhibitors, compounds **9ab**⁴⁴ and **SKI-II**⁴⁵ were also examined in living U937 cells (Table 6 and Figure 5). Compound **9ab** did not cause S1P reduction at 100 nM, which was expected

given its K_I values being 1.4 μM for SphK1 and 31 μM for SphK2.⁵² However, at a concentration of 1 μM , nearer to the K_I value of compound **9ab** at SphK1, a 40% reduction of S1P is observed. Comparing the K_I values for **9ab** versus those of the SphK1 selective compound **19a**, 110 nM for SphK1 and 26 μM for SphK2 (Table 6), suggests that the observed reduction in S1P levels for **19a** is accomplished through the inhibition of SphK1. **SKI-II** also fits this trend with a higher SphK1 K_I value of 12 μM ⁵² and no significant S1P reduction observed until 10 μM concentrations were applied.

A notable outlier in the series is the performance of oxazole **56** on whole cells. With the lowest K_I value in the series (47 nM for SphK1), **56** should inhibit S1P production most successfully. Compound **56** does reduce S1P levels significantly, along with the other amidine inhibitors, at a concentration of 100 nM, but fails to outperform compounds **19a** and **38** at 10 nM concentrations despite having the lowest K_I value. This recombinant enzyme versus living cell deviation in activity is subtle and suggests differences in uptake or efflux. Interestingly, S1P reduction in U937 cells by these amidine-based inhibitors did not cause caspase-mediated apoptosis as previous reports have demonstrated with other SphK inhibitors (data not shown).^{40, 42} However, a more thorough investigation beyond the characterization of these inhibitors is needed to better understand these differences in cytotoxicity.

Conclusion

The role of the SphKs as the sole producers of S1P, a lipid promoter for tumorigenesis and angiogenesis, in the sphingosine rheostat illuminates the practicality of an anti-cancer strategy that targets their activity.¹ Described herein is the optimization and SAR of amidine-based SphK1 subtype-selective inhibitors. The library of inhibitors evaluated were used as a test set in the generation of a SphK1 homology model from the crystal structure of DGKB, and used for the *in silico* design and synthesis of nanomolar SphK1 inhibitors. These inhibitors were found to significantly lower endogenous S1P levels in human leukemia U937 cells at 10 and 100 nM concentrations.

Experimental Section

Sphingosine Kinase Assay

Human SphK1 and mouse SphK2 cDNAs were used to generate mutant baculoviruses that encoded these proteins. Infection of Sf9 insect cells with the viruses for 72 h resulted in >1000-fold increases in SphK activity in 10000 g supernatant fluid from homogenized cell pellets. The enzyme assay conditions were exactly as described,⁵² except infected Sf9 cell extract containing 2–3 μg protein was used as a source of enzyme.

U937 Cell Culture Assay

U937 cells were grown according to previously described literature procedure.⁴⁰ In general, cells were grown in RPMI 1640 media enriched with L-glutamine, 10% penicillin and streptomycin and 10% fetal bovine serum (FBS). Twenty-four hours before dosing with SphK inhibitors, the media was replaced with media containing 2% FBS. All cell cultures were grown at a stable temperature of 37°C and the SphK inhibitors were dosed for 2 h.

S1P Extraction and LCMS Quantification

Extraction protocols and LCMS procedures were adapted from a previously reported study.⁶² Samples of pelleted cells (approximately 4 million) were taken up in 2 mL of 3:1 methanol:chloroform mixture and transferred to a capped glass vial. To this suspension was added 10 μL of internal standard solution containing 1 μM C17 S1P (purchased from Avanti

Polar Lipids). The mixture was homogenized via sonication for 10 min and immediately incubated at 48°C for 16 h. After this time, the mixture was cooled to ambient temperature and 200 μ L of 1 M KOH in methanol was added to the suspension. The samples were again sonicated and incubated at 37°C for an additional 2 h. After this time, the samples were neutralized through the addition of 30 μ L of glacial acetic acid and transferred to 2 mL microcentrifuge tubes. Samples were then centrifuge at 10,000 \times g for 10 min at 4°C. The supernatant fluid was collected in a separate glass vial and the pellets discarded. The resulting solution was evaporated (to a solid) with a stream of nitrogen. Immediately prior to LCMS analysis, the solid material was taken up in 300 μ L of methanol and centrifuged at 12,000 \times g for 12 min at 4°C. An auto-sampler vial was loaded with 150 μ L of the resulting supernatant for LCMS analysis.

SIP analysis from cellular extracts was performed on an Applied Biosystems 4000 QTrap LC/MS/MS instrument. Chromatographic resolution of analytes was achieved with a Shimadzu LC-20AD system. A binary solvent gradient with a flow rate of 1 mL/min was used to separate sphingolipid analytes by reverse phase chromatography (Supelco Discovery C18 column; 50 mm, 2.1 mm (L., I.D.); 5 μ m bead size). Mobile phase A was comprised of water: methanol: formic acid (79:20:1) and mobile phase B was comprised of methanol: formic acid (99:1). The run started with 100% A for 0.5 min. Solvent B was then increased linearly for 5.1 min to 100% of the total solvent composition and held at 100% for an additional 4.3 min. The column was finally re-equilibrated to 100% for 0.1 min and held for an additional 1 min. The following analytes (and fragmentation patterns) were monitored simultaneously for identification. C17SIP (366.4, 250.4); SIP (380.4, 264.4).

General Synthetic Materials and Methods

All nonaqueous reactions were carried out in oven or flame-dried glassware under an argon or nitrogen atmosphere with dry solvents and magnetic stirring, unless otherwise stated. The argon and nitrogen were dried by passing through a tube of Drierite. Anhydrous diethyl ether (Et₂O), chloroform (CHCl₃), Dimethyl sulfoxide (DMSO), toluene (PhMe), dichloromethane (CH₂Cl₂), methanol (MeOH), ethanol (EtOH), and tetrahydrofuran (THF) and *N,N*-dimethylformamide (DMF) were purchased from Aldrich or VMR Chemicals and used as received. THF was dried over activated molecular sieves (4 Å) prior to use. All other reagents were purchased from Acros chemicals and Aldrich chemicals. Except as indicated otherwise, reactions were monitored by thin layer chromatography (TLC) using 0.25 mm Whatman precoated silica gel plates. Flash chromatography was performed with the indicated solvents and Dynamic Adsorbents silica gel (particle size 0.023 – 0.040 mm). Proton (¹H) and carbon (¹³C) NMR spectra were recorded on a Varian UnityInova 500/51 or Varian UnityInova 300/54 at 300K unless otherwise noted. Chemical shifts are reported in ppm (δ) values relative to the solvent as follows: CDCl₃ (δ 7.24 for proton and δ 77.0 for carbon NMR), DMSO-d₆ (δ 2.50 for proton and δ 39.5 for carbon NMR) CD₃OD (δ 3.31 for proton and δ 47.6 for carbon NMR). All high-resolution mass spectrometry was carried out by the Mass Spectrometry Laboratory in the School of Chemical Sciences at the University of Illinois Urbana-Champaign (Urbana, IL).

TLC Stains—KMnO₄; 3 g KMnO₄ and 20 g K₂CO₃ in 300 mL water and 5 mL 5% NaOH. Seebach's Dip; To a solution of 25 g phosphomolybdic acid and 7.5 g cerium (IV) sulfate in 479 mL water was added 25 mL conc. sulfuric acid dropwise. Ninhydrin; 1.5 g ninhydrin in 5 mL AcOH and 500 mL 95% EtOH. All stains required TLC development on a hot plate set to 80°C.

Other abbreviations—1,1'-bis(diphenylphosphino)ferrocene (dppf), 4-dimethylaminopyridine (DMAP), 9-borabicyclo[3.3.1]nonane (9-BBN), acetic acid (AcOH),

benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), di-tert-butyl dicarbonate (Boc₂O), ethyl acetate (EtOAc), N,N-diisopropylethylamine (DIEA), tert-butanol (tBuOH), tetra-n-butylammonium bromide (TBAB), triethylamine (TEA), trifluoroacetic acid (TFA), trifluoroacetic anhydride (TFAA).

Liquid Chromatography and Mass Spectrometry for Evaluation of Chemical Purity

All compounds submitted for biological evaluation were determined to be > 95% pure by LCMS evaluation performed by the Mass Spectrometry Laboratory in the School of Chemical Sciences at the University of Illinois Urbana-Champaign (Urbana, IL). High performance liquid chromatography – mass spectrometry (LCMS) was carried out using an Agilent 2.1×50 mm C-18 column and a Micromass Q-tof Ultima mass spectrometer. Mobile phase A consisted of HPLC grade H₂O and 0.01% TFA; mobile phase B consisted of MeCN and 0.01% TFA. LCMS identification and purity utilized a binary gradient starting with 90% A and 10% B and linearly increasing to 100% B over the course of 6 min, followed by an isocratic flow of 100% B for an additional 3 min. A flow rate of 0.5 mL/min was maintained throughout the HPLC method. The purity of all products was determined by integration of the total ion count (TIC) spectra and integration of the ultraviolet (UV) spectra at 214 nm. Retention times are abbreviated as *t_R*; mass to charge ratios are abbreviated as *m/z*.

General Procedure A: Conversion of Nitriles to Amidines

To a solution of a nitrile (1.0 eq.) in MeOH (0.10 M) was added a 0.5 M solution of sodium methoxide in MeOH (0.50 eq.) at rt and then heated to 50°C for 24 h. The intermediate imidate was detectable by TLC; however, being in equilibrium with the nitrile, full conversion does not occur. Ammonium chloride (2.0 eq.) was then added in one portion at that temperature and allowed to react until the imidate was completely consumed by TLC analysis. The reaction was then cooled to rt and evacuated to dryness to yield a crude solid. The solid was reconstituted with CHCl₃ and filtered through a fine glass fritted funnel in order to remove excess ammonium chloride, and the filtrate was again evacuated to dryness. The material was then recrystallized in Et₂O to yield the pure amidine hydrochloride salt. The yields varied greatly depending upon substrate, because amidine formation is dependant upon the equilibrium ratio between nitrile and imidate established under the sodium methoxide conditions.

General Procedure B: PyBOP Mediated Couplings of Amines and Anilines to Carboxylic Acids

To a suspension of an amine or aniline (1.0 eq.), carboxylic acid (1.0 eq.), and PyBOP (1.1 eq.), in CH₂Cl₂ at rt was added DIEA (4.0 eq.) and let stir for 4 h unless otherwise stated. The reaction was then evaporated to dryness and immediately purified by flash chromatography.

General Procedure C: Williamson Ether Synthesis

To a solution of an alcohol (2 eq.) in DMF (0.3 M) at 0°C was added 60 % sodium hydride dispersed in mineral oil (2.0 eq.) at 0°C, then let warm to rt, and then let react for 45 min. The alkyl bromide was then added in one portion and the reaction was stirred for 12 h. The reaction was quenched with sat. NaHCO₃ (100x the volume of DMF) and extracted into EtOAc (100x the volume of DMF). The organic layer was washed 3x with neat water (100x the volume of DMF), dried with Na₂SO₄, evaporated to a yellow oil, and immediately purified by flash chromatography.

General Procedure D: Suzuki Coupling

To a solution of alkene (1.0 eq.) in THF (0.2 M) at rt was added a 0.5 M solution of 9-BBN in THF (2.0 eq.) and let stir until consumption of the alkene was evident by TLC analysis (4 h unless otherwise stated). The reaction was then treated with 3 M $K_3PO_4(aq)$, and diluted with DMF (0.2 M relative to the starting alkene). The aryl bromide and $PdCl_2(dppf)$ were then sequentially added and the reaction was let stir for 16 h. The reaction was diluted with EtOAc (200x the volume of DMF) and washed 3x with neat water (100x the volume of DMF). The organic layer was then dried with Na_2SO_4 , evaporated to a dark red oil, and immediately purified by flash chromatography.

General Procedure E: Aryl Nitro Reduction with Zinc Dust

To a solution of an aryl nitro (1.0 eq.) in AcOH (0.1 M) at rt was added zinc dust (10 eq.) in one portion and let stir for 16 h. The reaction was then diluted with EtOAc and filtered through Celite™. The filtrate was evaporated to dryness, coevaporated with PhMe to remove residual AcOH, and immediately purified by flash chromatography.

General Procedure F: Copper Mediated Alkane Synthesis

To a suspension of cuprous chloride (0.05 eq.) in Et_2O (1.0 M relative to the alkyl halide) at $-78^\circ C$ was added a 2.0 M solution of a Gignard reagent (2 eq.) in THF followed by the addition of an alkyl halide (Br or I) (1.0 eq.). The reaction was let warm to rt and held at that temperature until the starting alkene was judged consumed by TLC analysis (4 h unless otherwise stated). The reaction was then cooled to $0^\circ C$ and quenched with 1 N HCl (50x the volume of Et_2O) and extracted into EtOAc (50x the volume of Et_2O). The organic layer was then dried with Na_2SO_4 , evaporated to a dark green oil, and immediately purified by flash chromatography.

General Procedure G: Hydroboration/Oxidation

To a solution of alkene (1.0 eq.) in THF (1.0 M) at rt was added a 0.5 M solution of 9-BBN in THF (2.0 eq.) and let stir until consumption of the alkene was evident by TLC analysis (4 h unless otherwise stated). The reaction was then cooled to $0^\circ C$ and then diluted with EtOH (10 eq.), 3 M $NaOH(aq)$ (1.0 eq.), and slowly treated with 30% H_2O_2 in water (1.4 eq.) sequentially. The reaction was let warm to rt and then stir for 30 min before being quenched with 1 N HCl (equal to the total volume of THF) and extracted into EtOAc (10x the total volume of THF). The organic layer was then dried with Na_2SO_4 , evaporated to a colorless oil, and immediately purified by flash chromatography.

General Procedure H: Alkyl Mesylate Formation

To a solution of an alcohol (1.0 eq.) in CH_2Cl_2 (0.3 M) at $0^\circ C$ was added TEA (2.0 eq.) then methanesulfonyl chloride (1.1 eq.). The reaction was let warm to rt and then heated to reflux for 30 min. The reaction was then cooled to rt, quenched with sat. $NaHCO_3$ (10x the volume of CH_2Cl_2), and extracted into $CHCl_3$ (200x the volume of CH_2Cl_2). The organic layer was then dried with Na_2SO_4 , evaporated to a yellow oil, and immediately purified by flash chromatography.

General Procedure I: Alkyl Azide Formation

To a solution of an alkyl mesylate (1.0 eq.) in DMF (0.3 M) at rt was added sodium azide (1.1 eq.) and the reaction was heated to reflux for 12 h. The reaction was then cooled to rt, diluted with EtOAc (100x the volume of DMF), and washed 3x with sat. $NaHCO_3$ (100x the volume of DMF). The organic layer was then dried with Na_2SO_4 , evaporated to a yellow oil, and immediately purified by flash chromatography.

General Procedure J: Staudinger Reduction and Ligation

To a solution of an alkyl azide (1.0 eq.) and triphenylphosphine (1.1 eq.) in PhMe (0.3 M) was added neat water (2.0 eq.) and the reaction was heated to reflux for 30 min. The reaction was then cooled to rt and treated with a solution of 1-cyano-1-cyclopanecarboxylic acid (1.5 eq.), PyBOP (1.5 eq.), and TEA (2.0 eq.) in CH₂Cl₂ (1.5 M relative to the carboxylic acid). The reaction was let stir for 4 h, then evacuated to a dark red oil, and purified by flash chromatography.

General Procedure K: Pinnick Oxidation

To a solution of an aldehyde (1.0 eq.), NaH₂PO₄ (8.0 eq.), and 2-methyl-2-butene (10 eq.) in THF, water, and tBuOH (4:4:1) (0.04 M) at rt was added sodium chlorite (4 eq.) and let stir for 1 h. The reaction was diluted with EtOAc (10x the volume of the reaction's mixture of solvents), and washed 3x with 1 N HCl (5x the volume of the reaction's mixture of solvents). The organic layer was then dried with Na₂SO₄, and evaporated to a white solid. No further purification was necessary.

General Procedure L: Acid Chloride Formation

To a solution of a carboxylic acid (1.0 eq.) and DMF (0.05 eq.) in CH₂Cl₂ (0.1 M) at 0°C was added oxalyl chloride (2.0 eq.) dropwise and let warm to rt. The reaction progresses to a yellow green color and after 3 h the reaction was evaporated to dryness, and then immediately purified by flash chromatography.

General Procedure M: Acid Chloride and Amine Coupling

To a solution of an acid chloride (1.0 eq.) in CH₂Cl₂ (0.3 M) at rt was added DIEA (4.0 eq.) followed by an amine HCl salt (1.5 eq.) and the reaction was left stirring for 12 h. The reaction was then evaporated to dryness and immediately purified by flash chromatography.

General procedure N: Deprotection of N-Boc and O-tBu Ester Protecting Groups

To a solution of either a N-Boc or O-tBu protecting group (1.0 eq.) in CH₂Cl₂ (0.2 M) at rt was added TFA (0.2 M) and the reaction was reacted until judged complete by TLC analysis (30 min unless otherwise stated). The reaction was then evaporated to dryness and taken on crude.

1-cyano-N-tetradecylcyclopropanecarboxamide (3a)

General procedure B was used to couple tetradecan-1-amine (213 mg, 1.00 mmol) and 1-cyano-1-cyclopanecarboxylic acid to yield the title compound. 99%. White solid. R_f = 0.50 (20% EtOAc in hexanes; KMnO₄). ¹H NMR (300 MHz, CDCl₃) δ 6.41 (s, 1H), 3.27 (dt, J = 6.5, 5.3 Hz, 2H), 1.65 (dd, J = 8.1, 4.4 Hz, 2H), 1.52 (t, J = 6.9 Hz, 2H), 1.45 (dd, J = 8.0, 4.4 Hz, 2H), 1.36 – 1.11 (m, 22H), 0.86 (t, J = 6.7 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 165.22, 120.54, 40.89, 32.14, 29.87, 29.79, 29.71, 29.58, 29.45, 27.01, 22.91, 17.65, 14.34, 13.67.

1-cyano-N-hexadecylcyclopropanecarboxamide (3b)

General procedure B was used to couple hexadecan-1-amine (241 mg, 1.00 mmol) and 1-cyano-1-cyclopanecarboxylic acid to yield the title compound. 99%. White solid. R_f = 0.52 (20% EtOAc in hexanes; KMnO₄). ¹H NMR (500 MHz, CDCl₃) δ 6.37 (s, 1H), 3.28 (dt, J = 6.6, 5.3 Hz, 2H), 1.66 (dd, J = 8.1, 4.3 Hz, 2H), 1.58 – 1.49 (m, 2H), 1.47 (dd, J = 8.1, 4.3 Hz, 2H), 1.39 – 0.99 (m, 24H), 0.87 (t, J = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 164.99, 120.33, 40.68, 31.91, 29.67, 29.56, 29.48, 29.38, 29.22, 26.78, 22.68, 17.43, 14.12, 13.55.

1-cyano-*N*-octadecylcyclopropanecarboxamide (3c)

General procedure B was used to couple octadecan-1-amine (270 mg, 1.00 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 99%. White solid. $R_f = 0.55$ (20% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 6.44 (s, 1H), 3.26 (dt, $J = 6.6, 5.3$ Hz, 2H), 1.65 (dd, $J = 8.1, 4.3$ Hz, 2H), 1.52 (dt, $J = 13.7, 6.9$ Hz, 2H), 1.45 (dd, $J = 8.1, 4.3$ Hz, 2H), 1.26 (m, 26H), 0.86 (t, $J = 6.9$ Hz, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 164.96, 120.28, 40.64, 31.91, 29.68, 29.56, 29.48, 29.36, 29.22, 26.78, 22.67, 17.40, 14.11, 13.42.

1-carbamimidoyl-*N*-tetradecylcyclopropanecarboxamide hydrochloride (4a)

General procedure A was used to convert **3a** (306 mg, 1.00 mmol) to the title compound. 55%. White solid. $^1\text{H NMR}$ (300 MHz, DMSO) δ 9.11 (s, 2H), 8.97 (s, 2H), 7.80 (t, $J = 5.3$ Hz, 1H), 3.01 (dd, $J = 13.1, 6.5$ Hz, 2H), 1.65 – 0.96 (m, 28H), 0.83 (t, $J = 6.5$ Hz, 3H). $^{13}\text{C NMR}$ (75 MHz, DMSO) δ 168.54, 167.92, 40.13, 31.98, 29.74, 29.56, 29.48, 29.40, 29.09, 27.05, 22.78, 14.86, 14.65. LCMS: $t_R = 4.72$; $m/z = 324.3$. HRMS m/z calc. for $\text{C}_{19}\text{H}_{38}\text{N}_3\text{O}$ (M+H), 324.3015; found, 324.3010.

1-carbamimidoyl-*N*-hexadecylcyclopropanecarboxamide hydrochloride (4b)

General procedure A was used to convert **3b** (320 mg, 1.00 mmol) to the title compound. 46%. White solid. $^1\text{H NMR}$ (300 MHz, DMSO) δ 9.16 (s, 2H), 8.96 (s, 2H), 7.82 (s, 1H), 3.01 (d, $J = 5.1$ Hz, 2H), 1.51 – 0.97 (m, 30H), 0.83 (s, 3H). $^{13}\text{C NMR}$ (75 MHz, DMSO) δ 168.54, 167.92, 40.04, 31.98, 29.74, 29.56, 29.49, 29.40, 27.05, 22.79, 14.86, 14.65. LCMS: $t_R = 5.22$; $m/z = 352.3$. HRMS m/z calc. for $\text{C}_{21}\text{H}_{42}\text{N}_3\text{O}$ (M+H), 352.3328; found, 352.3329.

1-carbamimidoyl-*N*-octadecylcyclopropanecarboxamide hydrochloride (4c)

General procedure A was used to convert **3c** (362 mg, 1.00 mmol) to the title compound. 32%. White solid. $^1\text{H NMR}$ (300 MHz, DMSO) δ 9.07 (s, 2H), 8.95 (s, 2H), 7.89 (s, 1H), 3.05 (d, $J = 5.1$ Hz, 2H), 1.58 – 0.95 (m, 32H), 0.83 (s, 3H). $^{13}\text{C NMR}$ (75 MHz, DMSO) δ 168.64, 167.95, 40.09, 32.01, 29.78, 29.59, 29.54, 29.43, 27.12, 22.80, 14.92, 14.70. LCMS: $t_R = 6.22$; $m/z = 380.4$. HRMS m/z calc. for $\text{C}_{23}\text{H}_{46}\text{N}_3\text{O}$ (M+H), 380.3641; found, 380.3633.

((hept-6-en-1-yloxy)methyl)benzene (5a)

General procedure C was used to couple benzyl alcohol and 7-bromohept-1-ene (1.00 mL, 6.52 mmol) to yield the title compound. 87%. Yellow oil. $R_f = 0.88$ (10% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.57 – 7.19 (m, 5H), 5.89 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.22 – 4.89 (m, 2H), 4.57 (s, 2H), 3.54 (t, $J = 6.6$ Hz, 2H), 2.14 (m, 2H), 1.82 – 1.61 (m, 2H), 1.59 – 1.40 (m, 4H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 139.16, 139.01, 128.62, 127.86, 127.73, 114.65, 73.16, 70.66, 34.08, 29.97, 29.08, 26.04.

((hex-5-en-1-yloxy)methyl)cyclohexane (5b)

General procedure C was used to couple cyclohexylmethanol and 6-bromohex-1-ene (1.00 mL, 7.48 mmol) to yield the title compound. 70%. Clear and colorless oil. $R_f = 0.39$ (3% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.76 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.10 – 4.58 (m, 2H), 3.35 (t, $J = 6.4$, 2H), 3.15 (d, $J = 6.5$ Hz, 2H), 2.23 – 0.80 (m, 2H), 1.87 – 1.05 (m, 13H), 0.87 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 138.87, 114.59, 77.03, 71.03, 38.28, 33.80, 30.36, 29.42, 26.87, 26.10, 25.73.

((hept-6-en-1-yloxy)methyl)cyclohexane (5c)

General procedure C was used to couple cyclohexylmethanol and 7-bromohept-1-ene (1.00 mL, 6.52 mmol) to yield the title compound. 70%. Clear and colorless oil. $R_f = 0.73$ (5% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.75 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.07 – 4.70 (m, 2H), 3.32 (t, $J = 6.6$ Hz, 2H), 3.14 (d, $J = 6.6$ Hz, 2H), 2.15 – 1.90 (m, 2H), 1.84 – 0.98 (m, 15H), 0.98 – 0.65 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 139.04, 114.42, 77.03, 71.18, 38.27, 33.96, 30.37, 29.80, 28.98, 26.88, 26.10, 25.91.

((oct-7-en-1-yloxy)methyl)cyclohexane (5d)

General procedure C was used to couple cyclohexylmethanol and 8-bromooct-1-ene (1.00 mL, 5.98 mmol) to yield the title compound. 77%. Clear and colorless oil. $R_f = 0.43$ (3% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.77 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.13 – 4.71 (m, 2H), 3.35 (t, $J = 6.6$ Hz, 5H), 3.17 (d, $J = 6.5$ Hz, 2H), 2.12 – 1.91 (m, 2H), 1.86 – 1.01 (m, 17H), 0.98 – 0.74 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 139.18, 114.36, 77.03, 71.26, 38.29, 33.96, 30.39, 29.92, 29.19, 29.09, 26.89, 26.27, 26.11.

1-((hept-6-en-1-yloxy)methyl)adamantane (5e)

General procedure C was used to couple 1-adamantane-methanol and 7-bromohept-1-ene (1.00 mL, 6.52 mmol) to yield the title compound. 85%. Clear and colorless oil. $R_f = 0.54$ (5% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.79 (ddt, $J = 17.0, 10.2, 6.7$ Hz, 1H), 5.09 – 4.77 (m, 2H), 3.36 (t, $J = 6.5$ Hz, 2H), 2.94 (s, 2H), 2.12 – 1.86 (m, 5H), 1.79 – 0.99 (m, 18H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 139.14, 114.44, 82.10, 71.78, 39.97, 37.49, 34.00, 29.68, 29.00, 28.54, 25.90.

((hept-6-en-1-yloxy)methyl)cyclopentane (5f)

General procedure C was used to couple cyclopentylmethanol and 7-bromohept-1-ene (1.00 mL, 6.56 mmol) to yield the title compound. 79%. Clear and colorless oil. $R_f = 0.69$ (5% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.98 – 5.57 (m, 1H), 5.10 – 4.79 (m, 2H), 3.38 (t, $J = 6.6$ Hz, 2H), 3.25 (d, $J = 7.1, 2\text{H}$), 2.24 – 1.95 (m, 3H), 1.88 – 1.01 (m, 14H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 139.13, 114.45, 75.76, 71.17, 39.68, 33.97, 29.94, 29.81, 28.99, 25.92, 25.61.

7-butoxyhept-1-ene (5g)

General procedure C was used to couple butanol and 7-bromohept-1-ene (1.50 mL, 9.84 mmol) to yield the title compound. 75%. Clear and colorless oil. $R_f = 0.74$ (10% EtOAc in hexanes; KMnO_4). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.73 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.07 – 4.65 (m, 2H), 3.33 (m, 4H), 2.17 – 1.79 (m, 2H), 1.62 – 1.42 (m, 4H), 1.33 (m, 6H), 0.86 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 138.95, 114.38, 70.96, 70.75, 33.92, 32.05, 29.81, 28.95, 25.89, 19.53, 14.03.

1-(7-(benzyloxy)heptyl)-4-nitrobenzene (6a)

General procedure D was used to couple **5a** (564 mg, 2.76 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 61%. Yellow solid. $R_f = 0.16$ (5% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.13 (d, $J = 7.9$ Hz, 2H), 7.45 – 7.19 (m, 7H), 4.51 (s, 2H), 3.48 (t, $J = 6.4$ Hz, 2H), 2.70 (t, $J = 7.7$ Hz, 2H), 1.61 (m, 4H), 1.49 – 1.17 (m, 6H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 150.79, 146.20, 138.67, 129.16, 128.36, 127.62, 127.50, 123.55, 72.88, 70.39, 35.83, 30.92, 29.74, 29.23, 29.11, 26.11.

1-(6-(cyclohexylmethoxy)hexyl)-4-nitrobenzene (6b)

General procedure D was used to couple **5b** (1.02 g, 4.56 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 52%. Tan oil. $R_f = 0.56$ (5% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.15 (d, $J = 8.7$ Hz, 2H), 7.27 (d, $J = 7.8$ Hz, 2H), 3.34 (t, $J = 6.5$ Hz, 2H), 3.15 (d, $J = 6.6$ Hz, 2H), 2.80 – 2.58 (m, 2H), 1.86 – 1.00 (m, 17H), 1.00 – 0.77 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 150.97, 146.39, 129.36, 123.74, 77.05, 71.10, 38.25, 35.99, 31.15, 30.38, 29.81, 29.20, 26.88, 26.21, 26.11.

1-(7-(cyclohexylmethoxy)heptyl)-4-nitrobenzene (6c)

General procedure D was used to couple **5c** (951 mg, 4.52 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 63%. Tan oil. $R_f = 0.61$ (5% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.07 (d, $J = 8.7$ Hz, 2H), 7.27 (d, $J = 8.5$ Hz, 2H), 3.33 (t, $J = 6.5$ Hz, 2H), 3.14 (d, $J = 6.6$ Hz, 2H), 2.75 – 2.53 (m, 2H), 1.84 – 0.96 (m, 19H), 0.95 – 0.70 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 150.99, 146.36, 129.33, 123.70, 77.03, 71.18, 38.25, 36.02, 31.13, 30.37, 29.89, 29.43, 29.32, 26.88, 26.28, 26.10.

1-(8-(cyclohexylmethoxy)octyl)-4-nitrobenzene (6d)

General procedure D was used to couple **5d** (1.02 g, 4.56 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 60%. Tan oil. $R_f = 0.64$ (5% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.12 (d, $J = 8.6$ Hz, 2H), 7.30 (d, $J = 8.4$ Hz, 2H), 3.36 (t, $J = 6.6$ Hz, 2H), 3.17 (d, $J = 6.6$ Hz, 2H), 2.79 – 2.57 (m, 2H), 1.85 – 1.00 (m, 21H), 0.86 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 151.03, 146.41, 129.35, 123.76, 77.06, 71.26, 38.26, 36.07, 31.19, 30.39, 29.93, 29.56, 29.33, 26.89, 26.37, 26.11.

1-(((7-(4-nitrophenyl)heptyl)oxy)methyl)adamantane (6e)

General procedure D was used to couple **5e** (671 mg, 2.77 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 59%. Tan oil. $R_f = 0.74$ (10% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.15 (d, $J = 6.6$ Hz, 2H), 7.32 (m, $J = 6.6$ Hz, 2H), 3.36 (t, $J = 6.5$ Hz, 2H), 2.93 (s, 2H), 2.81 – 2.58 (m, 2H), 2.06 – 1.87 (m, 3H), 1.87 – 1.09 (m, 22H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 151.01, 142.80, 132.25, 124.11, 82.13, 71.82, 39.98, 37.48, 36.09, 29.78, 29.46, 29.37, 28.54, 26.27.

4-(7-(benzyloxy)heptyl)aniline (7a)

General procedure E was used to convert **6a** (215 mg, 0.657 mmol) to the title compound. 99%. Tan oil. $R_f = 0.27$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.51 – 7.26 (m, 5H), 7.02 (d, $J = 5.3$ Hz, 2H), 6.66 (m, $J = 5.3$ Hz, 2H), 4.57 (s, 2H), 3.52 (m, 4H), 2.70 – 2.42 (m, 2H), 1.80 – 1.53 (m, 4H), 1.42 (t, $J = 8.6$ Hz, 6H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.41, 139.03, 133.17, 129.42, 128.65, 127.94, 127.78, 115.48, 73.15, 70.80, 35.37, 32.09, 30.09, 29.69, 29.52, 26.48.

4-(6-(cyclohexylmethoxy)hexyl)aniline (7b)

General procedure E was used to convert **6b** (252 mg, 0.789 mmol) to the title compound. 99%. Clear and colorless oil. $R_f = 0.25$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 6.98 (d, $J = 8.1$ Hz, 2H), 6.62 (d, $J = 8.1$, 2H), 3.56 (s, 2H), 3.40 (t, $J = 6.2$, 2H), 3.21 (d, $J = 6.5$, 2H), 2.51 (t, $J = 7.6$ Hz, 2H), 1.93 – 1.04 (m, 17H), 1.04 – 0.73 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.33, 133.10, 129.36, 115.42, 77.07, 71.33, 38.30, 35.27, 32.04, 30.44, 29.95, 29.36, 26.96, 26.34, 26.17.

4-(7-(cyclohexylmethoxy)heptyl)aniline (7c)

General procedure E was used to convert **6c** (663 g, 2.00 mmol) to the title compound. 99%. Clear and colorless oil. $R_f = 0.34$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 6.99 (d, $J = 8.1$ Hz, 2H), 6.62 (d, $J = 8.2$ Hz, 2H), 3.58 (s, 2H), 3.40 (t, $J = 6.6$ Hz, 2H), 3.23 (d, $J = 6.6$ Hz, 2H), 2.62 – 2.41 (m, 2H), 1.97 – 1.04 (m, 19H), 1.06 – 0.83 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.36, 133.13, 129.37, 115.43, 77.10, 71.38, 38.32, 35.34, 32.07, 30.47, 30.02, 29.67, 29.50, 26.98, 26.44, 26.20.

4-(8-(cyclohexylmethoxy)octyl)aniline (7d)

General procedure E was used to convert **6d** (572 mg, 1.65 mmol) to the title compound. 99%. Clear and colorless oil. $R_f = 0.38$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 6.98 (d, $J = 8.2$ Hz, 2H), 6.62 (d, $J = 8.3$ Hz, 2H), 3.66 – 3.43 (m, 2H), 3.39 (t, $J = 6.7$ Hz, 2H), 3.21 (d, $J = 6.6$ Hz, 2H), 2.59 – 2.39 (m, 2H), 1.93 – 1.02 (m, 21H), 1.06 – 0.80 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.26, 133.25, 129.35, 115.43, 77.08, 71.37, 38.29, 35.32, 32.07, 30.43, 29.99, 29.70, 29.48, 26.94, 26.43, 26.16.

4-adamantan-1-ylmethoxyheptyl)aniline (7e)

General procedure E was used to convert **6e** (263 mg, 0.683 mmol) to the title compound. 99%. Clear and colorless oil. $R_f = 0.31$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 6.96 (d, $J = 7.8$ Hz, 2H), 6.62 (d, $J = 7.1$ Hz, 2H), 3.54 (s, 2H), 3.37 (t, $J = 6.6$ Hz, 2H), 2.95 (d, $J = 5.1$ Hz, 2H), 2.49 (t, $J = 6.3$ Hz, 2H), 1.96 (s, 3H), 1.85 – 1.19 (m, 22H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.22, 133.30, 129.36, 115.44, 82.11, 71.96, 39.98, 37.49, 35.30, 32.02, 29.82, 29.62, 29.47, 28.54, 26.33.

N-(4-(7-(benzyloxy)heptyl)phenyl)-1-cyanocyclopropanecarboxamide (8a)

General procedure B was used to couple **7a** (183 mg, 0.616 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 96%. Clear and colorless oil. $R_f = 0.47$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.13 (s, 1H), 7.41 (d, $J = 8.3$ Hz, 2H), 7.38 – 7.24 (m, 5H), 7.16 (d, $J = 8.3$ Hz, 2H), 4.51 (s, 2H), 3.48 (t, $J = 6.6$ Hz, 2H), 2.68 – 2.42 (m, 2H), 1.78 (dd, $J = 8.2, 4.3$ Hz, 2H), 1.70 – 1.52 (m, 6H), 1.46 – 1.26 (m, 6H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.54, 140.25, 138.93, 134.78, 129.19, 128.59, 127.88, 127.72, 120.86, 120.31, 73.09, 70.69, 35.59, 31.61, 29.99, 29.56, 29.39, 26.39, 18.49, 14.34.

1-cyano-N-(4-(6-(cyclohexylmethoxy)hexyl)phenyl)cyclopropanecarboxamide (8b)

General procedure B was used to couple **7b** (205 mg, 0.708 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 92%. Clear and colorless oil. $R_f = 0.48$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.12 (s, 1H), 7.32 (d, $J = 8.2$ Hz, 2H), 7.13 (d, $J = 8.2$ Hz, 2H), 3.36 (t, $J = 6.5$ Hz, 2H), 3.17 (d, $J = 6.5$ Hz, 2H), 2.67 – 2.25 (m, 2H), 1.90 – 1.02 (m, 21H), 1.02 – 0.52 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.50, 140.17, 134.75, 129.15, 120.83, 120.27, 77.04, 71.22, 38.27, 35.52, 31.60, 30.40, 29.88, 29.26, 26.91, 26.27, 26.13, 18.47, 14.31.

1-cyano-N-(4-(7-(cyclohexylmethoxy)heptyl)phenyl)cyclopropanecarboxamide (8c)

General procedure B was used to couple **7c** (288 mg, 0.950 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 93%. Clear and colorless oil. $R_f = 0.49$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.15 (s, 1H), 7.38 (d, $J = 8.2$ Hz, 2H), 7.11 (d, $J = 7.8$ Hz, 2H), 3.35 (t, $J = 6.6$ Hz, 2H), 3.19 (t, $J = 6.5$ Hz, 2H), 2.55 (t, $J = 7.6$ Hz, 2H), 1.89 – 0.98 (m, 23H), 0.89 (dd, $J = 21.8, 10.6$ Hz, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.52, 140.17, 134.79, 129.11, 120.86, 120.25, 77.04, 71.27, 38.26, 35.57, 31.60, 30.40, 29.94, 29.55, 29.38, 26.91, 26.35, 26.13, 18.45, 14.29.

1-cyano-N-(4-(8-(cyclohexylmethoxy)octyl)phenyl)cyclopropanecarboxamide (8d)

General procedure B was used to couple **7d** (160 mg, 0.504 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 86%. Clear and colorless oil. R_f = 0.62 (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.04 (s, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 3.36 (t, J = 6.6 Hz, 2H), 3.18 (d, J = 6.6 Hz, 2H), 2.73 – 2.31 (m, 2H), 1.89 – 1.02 (m, 25H), 1.02 – 0.68 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.47, 140.31, 134.69, 129.17, 120.78, 120.28, 77.05, 71.31, 38.26, 35.58, 31.64, 30.40, 29.95, 29.64, 29.38, 26.91, 26.39, 26.13, 18.44, 14.31.

N-(4-(7-adamantan-1-ylmethoxy)heptyl)phenyl)-1-cyanocyclopropanecarboxamide (8e)

General procedure B was used to couple **7e** (83 mg, 0.233 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 85%. Clear and colorless oil. R_f = 0.52 (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.01 (s, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 8.3 Hz, 2H), 3.36 (t, J = 6.6 Hz, 2H), 2.94 (d, J = 6.7 Hz, 2H), 2.70 – 2.43 (m, 2H), 1.95 (s, 3H), 1.85 – 1.28 (m, 26H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.45, 140.38, 134.60, 129.23, 120.71, 120.32, 82.10, 71.90, 39.96, 37.47, 35.58, 34.30, 31.62, 29.79, 29.54, 29.39, 28.52, 26.30, 18.48, 14.34.

N-(4-(7-(benzyloxy)heptyl)phenyl)-1-carbamimidoylcyclopropanecarboxamide hydrochloride (9a)

General procedure A was used to convert **8a** (230 mg, 0.590 mmol) to the title compound. 52%. White solid. $^1\text{H NMR}$ (500 MHz, DMSO) δ 9.54 (s, 1H), 9.15 (s, 2H), 8.88 (s, 2H), 7.44 (d, J = 8.3 Hz, 2H), 7.37 – 7.20 (m, 5H), 7.10 (d, J = 8.3 Hz, 2H), 4.40 (s, 2H), 3.38 (t, J = 6.4 Hz, 2H), 2.49 (t, J = 7.0 Hz, 2H), 1.66 – 1.35 (m, 8H), 1.26 (m, 6H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 172.78, 171.30, 143.91, 143.23, 141.18, 133.40, 132.57, 132.49, 126.14, 76.96, 74.74, 39.69, 36.13, 34.34, 33.81, 33.71, 30.84, 19.96. LCMS: t_R = 4.23; m/z = 408.3. HRMS m/z calc. for $\text{C}_{25}\text{H}_{34}\text{N}_3\text{O}_2$ (M+H), 408.2651; found, 408.2646.

1-carbamimidoyl-N-(4-(6-(cyclohexylmethoxy)hexyl)phenyl)cyclopropanecarboxamide hydrochloride (9b)

General procedure A was used to convert **8b** (248 mg, 0.648 mmol) to the title compound. 41%. White solid. $^1\text{H NMR}$ (300 MHz, DMSO) δ 9.67 (s, 1H), 9.03 (s, 4H), 7.47 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 3.27 (t, J = 6.3 Hz, 2H), 3.10 (d, J = 6.4 Hz, 2H), 2.49 (t, J = 5.0 Hz, 2H), 1.40 (m, 21H), 0.85 (dd, J = 21.4, 11.0 Hz, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 173.21, 171.45, 143.36, 141.52, 133.61, 126.28, 81.17, 75.51, 42.96, 39.92, 36.41, 35.01, 34.58, 33.81, 31.61, 30.96, 30.79, 20.13. LCMS: t_R = 4.44; m/z = 400.3. HRMS m/z calc. for $\text{C}_{24}\text{H}_{38}\text{N}_3\text{O}_2$ (M+H), 400.2964; found, 400.2958.

1-carbamimidoyl-N-(4-(7-(cyclohexylmethoxy)heptyl)phenyl)cyclopropanecarboxamide hydrochloride (9c)

General procedure A was used to convert **8c** (352 mg, 0.888 mmol) to the title compound. 43%. White solid. $^1\text{H NMR}$ (300 MHz, DMSO) δ 9.71 (s, 1H), 9.12 (s, 4H), 7.47 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 3.27 (t, J = 6.4 Hz, 2H), 3.12 (d, J = 5.9 Hz, 2H), 2.49 (t, J = 7.4 Hz, 2H), 1.78 – 0.97 (m, 23H), 0.85 (dd, J = 21.6, 10.9 Hz, 2H). $^{13}\text{C NMR}$ (75 MHz, DMSO) δ 168.53, 166.67, 138.61, 136.79, 128.84, 121.51, 76.43, 70.77, 38.21, 35.19, 31.64, 30.27, 29.84, 29.32, 29.23, 26.86, 26.34, 26.05, 15.36. LCMS: t_R = 4.65; m/z = 414.3. HRMS m/z calc. for $\text{C}_{25}\text{H}_{40}\text{N}_3\text{O}_2$ (M+H), 414.3121; found, 414.3111.

1-carbamimidoyl-N-(4-(8-(cyclohexylmethoxy)octyl)phenyl)cyclopropanecarboxamide hydrochloride (9d)

General procedure A was used to convert **8d** (178 mg, 0.434 mmol) to the title compound. 50%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.65 (s, 1H), 9.22 (s, 2H), 8.99 (s, 2H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.11 (d, *J* = 8.3 Hz, 2H), 3.29 (t, *J* = 6.3 Hz, 2H), 3.11 (d, *J* = 6.4 Hz, 2H), 2.50 (t, *J* = 7.4 Hz, 2H), 1.78 – 0.99 (m, 25H), 0.99 – 0.74 (m, 2H). ¹³C NMR (126 MHz, DMSO) δ 168.19, 166.47, 138.44, 136.51, 128.62, 121.33, 76.20, 70.55, 37.98, 35.00, 31.39, 30.03, 29.62, 29.24, 28.98, 26.63, 26.14, 25.82, 15.16. LCMS: *t*_R = 4.86; *m/z* = 428.3. HRMS *m/z* calc. for C₂₆H₄₂N₃O₂ (M+H), 428.3277; found, 428.3277.

N-(4-(7-((adamantan-1-ylmethoxy)heptyl)phenyl)-1-carbamimidoylcyclopropanecarboxamide hydrochloride (9e)

General procedure A was used to convert **8e** (79 mg, 0.176 mmol) to the title compound. 22%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.56 (s, 1H), 9.17 (s, 2H), 8.88 (s, 2H), 7.44 (d, *J* = 8.5 Hz, 2H), 7.10 (d, *J* = 8.5 Hz, 2H), 3.28 (t, *J* = 6.4 Hz, 2H), 2.88 (s, 2H), 2.50 (m, 2H), 1.89 (m, 2H), 1.65 (d, *J* = 12.1 Hz, 3H), 1.60 – 1.25 (s, 26H). ¹³C NMR (126 MHz, DMSO) δ 176.39, 168.07, 167.14, 166.50, 163.30, 138.48, 136.45, 134.79, 128.61, 121.35, 81.37, 71.06, 37.16, 34.94, 34.08, 31.37, 29.93, 29.44, 28.97, 28.04, 26.04, 15.18. LCMS: *t*_R = 5.65; *m/z* = 466.4. HRMS *m/z* calc. for C₂₉H₄₅N₃O₂ (M+H), 466.3434; found, 466.3424.

non-8-en-1-ylbenzene (10a)

General procedure F was used to couple benzylmagnesium bromide and 8-bromooct-1-ene (1.00 mL, 5.98 mmol) to yield the title compound. 84%. Clear and colorless oil. *R*_f = 0.75 (hexanes; KMnO₄). ¹H NMR (300 MHz, CDCl₃) δ 7.50 – 6.98 (m, 5H), 5.84 (ddt, *J* = 16.9, 10.2, 6.7 Hz, 1H), 5.20 – 4.82 (m, 2H), 2.78 – 2.47 (m, 2H), 1.89 (dt, *J* = 7.0, 6.8 Hz, 2H), 1.64 (p, *J* = 7.0 Hz, 2H), 1.55 – 1.21 (m, 8H). ¹³C NMR (75 MHz, CDCl₃) δ 143.09, 139.38, 128.63, 128.45, 125.81, 114.67, 114.42, 36.26, 34.09, 31.80, 29.56, 29.35, 29.20.

oct-7-en-1-ylbenzene (10b)

General procedure F was used to couple benzylmagnesium bromide and 7-bromohept-1-ene (1.00 mL, 6.52 mmol) to yield the title compound. 84%. Clear and colorless oil. *R*_f = 0.75 (hexanes; KMnO₄). ¹H NMR (300 MHz, CDCl₃) δ 7.65 – 7.15 (m, 5H), 5.97 (ddt, *J* = 16.9, 10.0, 6.7 Hz, 1H), 5.13 (m, 2H), 2.98 – 2.56 (m, 2H), 2.21 (dt, *J* = 6.9, 6.5 Hz, 2H), 1.97 – 1.67 (m, 2H), 1.67 – 1.28 (m, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 143.17, 139.42, 128.76, 128.59, 125.95, 114.60, 36.37, 34.20, 31.88, 29.56, 29.41, 29.26.

1-nitro-4-(9-phenylnonyl)benzene (11a)

General procedure D was used to couple **10a** (971 mg, 4.80 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 59%. Tan oil. *R*_f = 0.67 (10% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 8.18 (d, *J* = 8.6 Hz, 2H), 7.42 – 7.30 (m, 4H), 7.30 – 7.18 (m, 3H), 2.72 (m, 4H), 1.66 (m, 24.4 Hz, 4H), 1.39 (m, 10H). ¹³C NMR (75 MHz, CDCl₃) δ 151.12, 146.49, 143.12, 129.45, 128.70, 128.55, 125.90, 123.81, 36.33, 36.15, 31.87, 31.31, 29.82, 29.75, 29.66, 29.53.

1-nitro-4-(8-phenyloctyl)benzene (11b)

General procedure D was used to couple **10b** (1.00 g, 5.31 mmol) and 1-bromo-4-nitrobenzene to yield the title compound. 71%. Tan oil. *R*_f = 0.49 (5% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 8.16 (d, *J* = 8.8 Hz, 2H), 7.39 – 7.27 (m, 4H), 7.27 – 7.15 (m, 3H), 2.72 – 2.60 (m, 4H), 1.78 – 1.48 (m, 4H), 1.40 (d, *J* = 19.9 Hz, 8H). ¹³C NMR (75 MHz, CDCl₃) δ 151.09, 146.46, 143.08, 129.42, 128.67, 128.52, 125.87, 123.81, 36.25, 36.12, 31.78, 31.26, 29.67, 29.63, 29.55, 29.45.

4-(9-phenylnonyl)aniline (12a)

General procedure E was used to convert **11a** (426 mg, 1.42 mmol) to the title compound. 99%. Tan oil. $R_f = 0.33$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.48 – 7.20 (m, 5H), 7.08 (d, $J = 8.3$ Hz, 2H), 6.74 (d, $J = 8.3$ Hz, 2H), 3.58 (s, 2H), 2.87 – 2.66 (m, 2H), 2.66 – 2.53 (m, 2H), 1.86 – 1.57 (m, 4H), 1.42 (s, 10H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.38, 143.27, 133.31, 129.46, 128.76, 128.58, 125.91, 115.54, 36.36, 35.45, 32.21, 31.90, 29.91, 29.71, 29.65.

4-(8-phenyloctyl)aniline (12b)

General procedure E was used to convert **11b** (572 mg, 1.65 mmol) to the title compound. 99%. Tan oil. $R_f = 0.31$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.52 – 7.20 (m, 5H), 7.11 (d, $J = 8.3$ Hz, 2H), 6.73 (d, $J = 8.3$ Hz, 2H), 3.81 – 3.37 (m, 2H), 2.77 (m, 2H), 2.63 (m, 2H), 1.72 (m, 4H), 1.43 (d, $J = 19.9$ Hz, 8H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 144.45, 143.29, 133.31, 129.50, 128.81, 128.63, 125.96, 115.58, 36.40, 35.49, 32.25, 31.95, 29.90, 29.75, 29.69.

1-cyano-N-(4-(9-phenylnonyl)phenyl)cyclopropanecarboxamide (13a)

General procedure B was used to couple **12a** (251 mg, 0.850 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 94%. Clear and colorless oil. $R_f = 0.56$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.12 (s, 1H), 7.44 (d, $J = 8.4$ Hz, 2H), 7.37 – 7.09 (m, 7H), 2.62 (m, 4H), 1.80 (dd, $J = 8.2, 4.4$ Hz, 2H), 1.74 – 1.47 (m, 6H), 1.34 (s, 10H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.53, 143.15, 140.34, 134.78, 129.22, 128.66, 128.49, 125.83, 120.84, 120.33, 36.26, 35.64, 31.79, 31.70, 29.76, 29.59, 29.48, 18.50, 14.37.

1-cyano-N-(4-(8-phenyloctyl)phenyl)cyclopropanecarboxamide (13b)

General procedure B was used to couple **12b** (485 mg, 1.72 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 91%. Clear and colorless oil. $R_f = 0.54$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.19 (s, 1H), 7.45 (d, $J = 8.4$ Hz, 2H), 7.39 – 7.28 (m, 2H), 7.28 – 7.12 (m, 5H), 2.64 (m, 4H), 1.81 (dd, $J = 8.2, 4.4$ Hz, 2H), 1.75 – 1.50 (m, 6H), 1.50 – 1.21 (m, 8H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 163.59, 143.14, 140.29, 134.85, 129.22, 128.68, 128.52, 125.86, 120.91, 120.35, 36.27, 35.65, 31.81, 31.72, 29.72, 29.60, 29.49, 18.52, 14.38.

1-carbamimidoyl-N-(4-(9-phenylnonyl)phenyl)cyclopropanecarboxamide hydrochloride (14a)

General procedure A was used to convert **13a** (312 mg, 0.803 mmol) to the title compound. 44%. White solid. $^1\text{H NMR}$ (500 MHz, DMSO) δ 9.61 (s, 1H), 9.21 (s, 2H), 8.97 (s, 2H), 7.46 (d, $J = 8.3$ Hz, 2H), 7.29 – 7.19 (m, 2H), 7.18 – 7.05 (m, 5H), 2.58 – 2.48 (m, 4H), 1.69 – 1.31 (m, 8H), 1.23 (s, 10H). $^{13}\text{C NMR}$ (126 MHz, DMSO) δ 168.18, 166.48, 142.74, 138.45, 136.48, 128.68, 128.64, 126.01, 121.35, 35.59, 34.97, 31.44, 29.39, 29.26, 29.06, 29.00, 15.16. LCMS: $t_R = 4.79$; $m/z = 406.3$. HRMS m/z calc. for $\text{C}_{26}\text{H}_{36}\text{N}_3\text{O}$ (M+H), 406.2858; found, 406.2852.

1-carbamimidoyl-N-(4-(9-phenylnonyl)phenyl)cyclopropanecarboxamide hydrochloride (14b)

General procedure A was used to convert **13b** (560 mg, 1.50 mmol) to the title compound. 39%. White solid. $^1\text{H NMR}$ (300 MHz, DMSO) δ 10.50 (s, 2H), 9.62 (s, 1H), 8.89 (s, 2H), 7.45 (d, $J = 7.9$ Hz, 2H), 7.17 (m, 7H), 2.71 – 2.24 (m, 4H), 1.92 – 0.92 (m, 14H). $^{13}\text{C NMR}$ (75 MHz, DMSO) δ 170.61, 168.67, 166.78, 142.98, 138.63, 136.80, 128.91, 128.87, 126.25, 123.40, 121.59, 35.82, 35.20, 31.67, 30.30, 29.49, 29.30, 29.24, 16.07, 15.23.

LCMS: $t_R = 4.51$; $m/z = 392.3$. HRMS m/z calc. for $C_{25}H_{34}N_3O$ (M+H), 392.2702; found, 392.2695.

((dec-9-en-1-yloxy)methyl)cyclohexane (15a)

General procedure C was used to couple cyclohexylmethanol and 10-bromodec-1-ene (4.35 mL, 21.7 mmol) to yield the title compound. 74%. Clear and colorless oil. $R_f = 0.86$ (10% EtOAc in hexanes; $KMnO_4$). 1H NMR (300 MHz, $CDCl_3$) δ 5.74 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.13 – 4.74 (m, 2H), 3.36 (t, $J = 6.6$ Hz, 2H), 3.17 (d, $J = 6.6$ Hz, 2H), 2.02 (dt, $J = 9.9, 4.0$ Hz, 2H), 1.90 – 0.99 (m, 21H), 0.98 – 0.70 (m, 2H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 139.30, 114.31, 77.05, 71.32, 38.29, 34.03, 30.40, 29.97, 29.66, 29.30, 29.14, 26.90, 26.40, 26.12.

((dec-9-en-1-yloxy)methyl)cyclopentane (15b)

General procedure C was used to couple cyclopentylmethanol and 10-bromodec-1-ene (1.00 mL, 4.98 mmol) to yield the title compound. 76%. Clear and colorless oil. $R_f = 0.85$ (10% EtOAc in hexanes; $KMnO_4$). 1H NMR (300 MHz, $CDCl_3$) δ 5.80 (ddt, $J = 16.9, 10.2, 6.7$ Hz, 1H), 5.17 – 4.75 (m, 2H), 3.39 (t, $J = 6.7$ Hz, 2H), 3.26 (d, $J = 7.1$ Hz, 2H), 2.15 (dp, $J = 15.0, 7.4$ Hz, 1H), 2.03 (m, 2H), 1.82 – 0.70 (m, 21H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 139.39, 114.32, 75.77, 71.29, 39.67, 34.04, 29.94, 29.83, 29.67, 29.31, 29.14, 26.40, 25.62.

10-(cyclohexylmethoxy)decan-1-ol (16a)

General procedure G was used to convert **15a** (4.00 g, 15.8 mmol) to the title compound. 81%. Clear and colorless oil. $R_f = 0.68$ (30% EtOAc in hexanes; Seebach's Dip). 1H NMR (500 MHz, $CDCl_3$) δ 3.64 (s, 1H), 3.42 (t, $J = 6.7$ Hz, 2H), 3.23 (t, $J = 6.7$ Hz, 2H), 3.04 (d, $J = 6.6$ Hz, 2H), 1.67 – 1.48 (m, 5H), 1.48 – 1.32 (m, 5H), 1.24 – 0.93 (m, 13H), 0.85 – 0.66 (m, 2H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 76.66, 70.97, 62.19, 37.84, 32.53, 30.00, 29.54, 29.49, 29.46, 29.38, 26.54, 26.03, 25.75.

10-(cyclopentylmethoxy)decan-1-ol (16b)

General procedure G was used to convert **15b** (902 mg, 3.78 mmol) to the title compound. 85%. Clear and colorless oil. $R_f = 0.65$ (30% EtOAc in hexanes; Seebach's Dip). 1H NMR (300 MHz, $CDCl_3$) δ 3.69 (s, 1H), 3.38 (t, $J = 6.7$ Hz, 2H), 3.24 (t, $J = 5.9$ Hz, 2H), 3.05 (d, $J = 6.3$ Hz, 2H), 2.14 (sept., $J = 7.4$ Hz, 1H), 1.96 – 0.49 (m, 24H).

(((10-azidodecyl)oxy)methyl)cyclohexane (17a)

General procedure H was used to convert **16a** (2.35 g, 8.69 mmol) to 10-(cyclohexylmethoxy)decyl methanesulfonate. 98%. Clear and colorless oil. $R_f = 0.26$ (10% EtOAc in hexanes; Seebach's Dip). 1H NMR (500 MHz, $CDCl_3$) δ 4.07 (t, $J = 6.6$ Hz, 2H), 3.23 (t, $J = 6.5$ Hz, 2H), 3.05 (d, $J = 6.6$, 2H), 2.86 (s, 3H), 1.69 – 1.48 (m, 7H), 1.48 – 1.35 (m, 3H), 1.35 – 0.94 (m, 15H), 0.86 – 0.68 (m, 2H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 76.61, 70.88, 70.15, 37.94, 36.99, 30.02, 29.62, 29.33, 29.30, 29.23, 28.98, 28.89, 26.56, 26.04, 25.78, 25.28. General procedure I was then used to convert the alkyl mesylate (2.05 g, 5.88 mmol) to the title compound. 94%. Clear and colorless oil. $R_f = 0.93$ (10% EtOAc in hexanes; Seebach's Dip). 1H NMR (500 MHz, $CDCl_3$) δ 3.30 (t, $J = 6.6$ Hz, 2H), 3.17 (t, $J = 7.0$ Hz, 2H), 3.12 (d, $J = 6.6$ Hz, 2H), 1.74 – 1.56 (m, 5H), 1.56 – 1.40 (m, 5H), 1.35 – 1.00 (m, 15H), 0.94 – 0.76 (m, 2H). ^{13}C NMR (126 MHz, $CDCl_3$) δ 76.71, 70.98, 51.33, 38.03, 30.10, 29.69, 29.42, 29.37, 29.07, 28.78, 26.63, 26.12, 25.85.

(((10-azidodecyl)oxy)methyl)cyclopentane (17b)

General procedure H was used to convert **16b** (904 mg, 3.21 mmol) to 10-(cyclohexylmethoxy)decyl methanesulfonate. $R_f = 0.22$ (10% EtOAc in hexanes; Seebach's

Dip). The alkyl mesylate was not purified by flash chromatography in the example, and was taken on to the next step crude. This method was later shown to be inferior to that of the synthesis of **17a**. General procedure I was then used to convert the alkyl mesylate to the title compound. 63% over 2 steps. Clear and colorless oil. $R_f = 0.93$ (10% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 3.38 (t, $J = 6.6$ Hz, 2H), 3.29 – 3.14 (m, 4H), 2.24 – 1.94 (m, 1H), 1.93 – 0.55 (m, 24H).

1-cyano-*N*-(10-(cyclohexylmethoxy)decyl)cyclopropanecarboxamide (**18a**)

General procedure J was used to couple **17a** (1.55 g, 5.25 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 82%. Clear and colorless oil. $R_f = 0.56$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 6.59 (t, $J = 5.4$ Hz, 1H), 3.25 (t, $J = 6.6$ Hz, 2H), 3.14 (dt, $J = 6.6, 5.4$ Hz, 2H), 3.06 (d, $J = 6.6$ Hz, 2H), 1.67 – 1.35 (m, 12H), 1.33 (m, 2H), 1.26 – 0.95 (m, 15H), 0.79 (m, 2H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 164.86, 120.06, 76.64, 70.92, 40.48, 37.95, 30.04, 29.63, 29.38, 29.33, 29.26, 29.11, 26.68, 26.57, 26.06, 25.79, 17.22, 13.28.

1-cyano-*N*-(10-(cyclopentylmethoxy)decyl)cyclopropanecarboxamide (**18b**)

General procedure J was used to couple **17b** (569 mg, 2.02 mmol) and 1-cyano-1-cyclopropanecarboxylic acid to yield the title compound. 84%. Clear and colorless oil. $R_f = 0.54$ (20% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 6.52 (s, 1H), 3.32 (t, $J = 6.6$ Hz, 2H), 3.19 (d, $J = 7.1$ Hz, 2H), 2.07 (sept., $J = 7.4$ Hz, 1H), 1.77 – 0.99 (m, 28H).

1-carbamimidoyl-*N*-(10-(cyclohexylmethoxy)decyl)cyclopropanecarboxamide hydrochloride (**19a**)

General procedure A was used to convert **18a** (1.56 g, 4.30 mmol) to the title compound. 44%. White solid. $^1\text{H NMR}$ (500 MHz, DMSO) δ 9.04 (s, 4H), 7.83 (t, $J = 5.6$ Hz, 1H), 3.28 (t, $J = 6.5$ Hz, 2H), 3.11 (d, $J = 6.4$ Hz, 2H), 3.02 (dt, $J = 6.7, 5.6$ Hz, 2H), 1.71 – 1.54 (m, 5H), 1.53 – 1.00 (m, 24H), 0.94 – 0.76 (m, 2H). $^{13}\text{C NMR}$ (126 MHz, DMSO) δ 168.34, 167.68, 76.20, 70.56, 37.97, 30.03, 29.64, 29.47, 29.42, 29.32, 29.23, 26.82, 26.62, 26.17, 25.81, 14.62. LCMS: $t_R = 4.29$; $m/z = 380.3$. HRMS m/z calc. for $\text{C}_{22}\text{H}_{42}\text{N}_3\text{O}_2$ (M+H), 380.3277; found, 380.3268.

1-carbamimidoyl-*N*-(10-(cyclohexylmethoxy)decyl)cyclopropanecarboxamide hydrochloride (**19b**)

General procedure A was used to convert **18b** (591 mg, 1.70 mmol) to the title compound. 29%. White solid. $^1\text{H NMR}$ (500 MHz, DMSO) δ 9.08 (s, 4H), 7.78 (t, $J = 5.4$ Hz, 1H), 3.34 – 3.28 (m, 2H), 3.18 (d, $J = 7.0$ Hz, 2H), 3.03 (td, $J = 6.8, 5.4$ Hz, 2H), 2.12 – 1.95 (m, 1H), 1.68 – 1.57 (m, 2H), 1.57 – 1.31 (m, 10H), 1.31 – 1.10 (m, 16H). $^{13}\text{C NMR}$ (126 MHz, DMSO) δ 168.15, 167.73, 74.92, 70.52, 39.37, 29.63, 29.54, 29.46, 29.41, 29.34, 29.22, 28.91, 26.81, 26.17, 25.42, 16.85, 14.62. LCMS: $t_R = 4.08$; $m/z = 366.3$. HRMS m/z calc. for $\text{C}_{21}\text{H}_{40}\text{N}_3\text{O}_2$ (M+H), 366.3121; found, 366.3111.

4-(7-(cyclohexylmethoxy)heptyl)benzaldehyde (**20a**)

General procedure D was used to couple **5c** (1.08 g, 5.12 mmol) and 4-bromobenzaldehyde to yield the title compound. 77%. Clear and colorless oil. $R_f = 0.60$ (10% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 9.94 (t, $J = 2.0$ Hz, 1H), 7.76 (d, $J = 8.2$ Hz, 2H), 7.30 (d, $J = 8.0$ Hz, 2H), 3.34 (t, $J = 6.6$ Hz, 2H), 3.16 (d, $J = 6.6$ Hz, 2H), 2.74 – 2.52 (m, 2H), 1.84 – 1.03 (m, 19H), 0.87 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 191.83, 150.40, 134.57, 129.96, 129.17, 76.94, 71.13, 38.22, 36.29, 31.16, 30.32, 29.88, 29.43, 29.35, 26.84, 26.27, 26.07.

4-(7-(cyclopentylmethoxy)heptyl)benzaldehyde (20b)

General procedure D was used to couple **5f** (500 mg, 2.55 mmol) and 4-bromobenzaldehyde to yield the title compound. 77%. Clear and colorless oil. $R_f = 0.72$ (10% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 9.89 (s, 1H), 7.72 (d, $J = 8.0$ Hz, 2H), 7.26 (d, $J = 8.1$ Hz, 2H), 3.33 (t, $J = 6.6$ Hz, 2H), 3.19 (d, $J = 7.1$ Hz, 2H), 2.68 – 2.49 (m, 2H), 2.08 (sept., $J = 7.4$ Hz, 1H), 1.77 – 1.37 (m, 10H), 1.28 – 1.06 (m, 8H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 191.97, 150.49, 134.59, 130.01, 129.22, 75.69, 71.13, 39.65, 36.34, 31.18, 29.88, 29.78, 29.45, 29.37, 26.29, 25.60.

4-(7-butoxyheptyl)benzaldehyde (20c)

General procedure D was used to couple **5g** (1.26 g, 7.39 mmol) and 4-bromobenzaldehyde to yield the title compound. 89%. Clear and colorless oil. $R_f = 0.48$ (10% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 9.83 (s, 1H), 7.66 (d, $J = 8.2$ Hz, 2H), 7.19 (d, $J = 8.2$ Hz, 2H), 3.26 (m, 4H), 2.70 – 2.35 (m, 2H), 1.60 – 1.06 (m, 14H), 0.77 (t, $J = 7.5$ Hz, 3H). $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 191.53, 150.12, 134.33, 129.69, 128.90, 70.68, 70.46, 36.03, 31.78, 30.90, 29.65, 29.18, 29.08, 26.02, 19.29, 13.84.

***N*-(1-cyanocyclopropyl)-4-(7-(cyclohexylmethoxy)heptyl)benzamide (22a)**

General procedure K was used to convert **20a** (1.25 g, 3.94 mmol) to its corresponding carboxylic acid **21a**, which was taken on to the next reaction crude. General procedure I was then used to convert the crude carboxylic acid to its acid chloride and was used immediately after purification. General procedure M was used to couple the acid chloride and 1-amino-1-cyclopropanecarbonitrile to yield the title compound. 57% over 3 steps. While solid. $R_f = 0.52$ (40% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.68 (dd, $J = 8.3, 2.7$ Hz, 2H), 7.34 – 7.12 (m, 2H), 6.97 (d, $J = 20.0$ Hz, 1H), 3.36 (td, $J = 6.6, 2.9$ Hz, 2H), 3.18 (dd, $J = 6.6, 2.8$ Hz, 2H), 2.63 (dd, $J = 10.1, 5.2$ Hz, 2H), 1.87 – 0.99 (m, 25H), 0.99 – 0.73 (m, 2H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 168.63, 148.03, 130.24, 128.87, 127.66, 120.65, 77.06, 71.26, 38.22, 36.03, 31.30, 30.37, 29.90, 29.49, 29.37, 26.87, 26.31, 26.09, 21.11, 16.99.

***N*-(1-cyanocyclopropyl)-4-(7-(cyclopentylmethoxy)heptyl)benzamide (22b)**

General procedure K was used to convert **20b** (536 mg, 1.77 mmol) to its corresponding carboxylic acid **21b**, which was taken on to the next reaction crude. General procedure I was then used to convert the crude carboxylic acid to its acid chloride and was used immediately after purification. General procedure M was used to couple the acid chloride and 1-amino-1-cyclopropanecarbonitrile to yield the title compound. 61% over 3 steps. While solid. $R_f = 0.48$ (40% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 7.91 (s, 1H), 7.71 (d, $J = 8.2$ Hz, 2H), 7.15 (d, $J = 8.2$ Hz, 2H), 3.36 (t, $J = 9.6$ Hz, 2H), 3.22 (d, $J = 7.2$ Hz, 2H), 2.58 (t, $J = 6.6$ Hz, 2H), 2.18 – 2.00 (m, 1H), 1.80 – 0.98 (m, 22H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 168.68, 147.90, 130.29, 128.80, 127.71, 120.70, 75.76, 71.20, 39.63, 36.02, 31.29, 29.87, 29.81, 29.49, 29.36, 26.31, 25.59, 21.11, 16.92.

4-(7-butoxyheptyl)-*N*-(1-cyanocyclopropyl)benzamide (22c)

General procedure K was used to convert **20c** (1.40 g, 5.07 mmol) to its corresponding carboxylic acid **21c**, which was taken on to the next reaction crude. General procedure I was then used to convert the crude carboxylic acid to its acid chloride and was used immediately after purification. General procedure M was used to couple the acid chloride and 1-amino-1-cyclopropanecarbonitrile to yield the title compound. 78% over 3 steps. While solid. $R_f = 0.32$ (40% EtOAc in hexanes; Seebach's Dip). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 8.20 (s, 1H), 7.73 (d, $J = 8.1$ Hz, 2H), 7.13 (d, $J = 8.1$ Hz, 2H), 3.57 – 3.13 (m, 4H), 2.53 (m, 2H), 1.64 – 1.42 (m, 8H), 1.42 – 1.13 (m, 10H), 0.86 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ

169.04, 147.95, 130.24, 128.83, 127.77, 120.80, 71.05, 70.83, 36.01, 32.02, 31.29, 29.92, 29.48, 29.36, 26.31, 21.15, 19.56, 16.87, 14.16.

***N*-(1-carbamimidoylcyclopropyl)-4-(7-(cyclohexylmethoxy)heptyl)benzamide hydrochloride (23a)**

General procedure A was used to convert **22a** (890 mg, 2.25 mmol) to the title compound. 71%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.12 (s, 1H), 8.86 (s, 2H), 8.57 (s, 2H), 7.82 (d, *J* = 8.2 Hz, 2H), 7.26 (d, *J* = 8.2 Hz, 2H), 3.28 (t, *J* = 6.4 Hz, 2H), 3.11 (d, *J* = 6.4 Hz, 2H), 2.60 (t, *J* = 7.5 Hz, 2H), 1.78 – 0.52 (m, 25H). ¹³C NMR (126 MHz, CDCl₃) δ 177.08, 172.73, 151.72, 135.97, 133.16, 133.08, 80.94, 75.27, 42.72, 40.10, 37.82, 35.92, 34.78, 34.34, 33.80, 33.69, 31.37, 30.85, 30.55, 23.17. LCMS: *t*_R = 4.36; *m/z* = 414.3. HRMS *m/z* calc. for C₂₅H₄₀N₃O₂ (M+H), 414.3121; found, 414.3111.

***N*-(1-carbamimidoylcyclopropyl)-4-(7-(cyclopentylmethoxy)heptyl)benzamide hydrochloride (23b)**

General procedure A was used to convert **22b** (413 mg, 1.08 mmol) to the title compound. 73%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.15 (s, 1H), 8.94 (s, 2H), 8.60 (s, 2H), 7.81 (d, *J* = 7.6 Hz, 2H), 7.26 (d, *J* = 7.6 Hz, 2H), 3.30 (t, *J* = 5.6 Hz, 2H), 3.17 (d, *J* = 7.0 Hz, 2H), 2.60 (t, *J* = 7.4 Hz, 2H), 2.13 – 1.94 (m, 1H), 1.75 – 1.01 (m, 22H). ¹³C NMR (126 MHz, DMSO) δ 172.42, 167.98, 146.94, 131.23, 128.41, 128.35, 74.92, 70.49, 35.35, 33.06, 31.16, 29.59, 29.54, 29.05, 28.95, 26.10, 25.42, 18.41. LCMS: *t*_R = 4.29; *m/z* = 400.3. HRMS *m/z* calc. for C₂₄H₃₈N₃O₂ (M+H), 400.2964; found, 400.2957.

4-(7-butoxyheptyl)-*N*-(1-carbamimidoylcyclopropyl)benzamide hydrochloride (23c)

General procedure A was used to convert **22c** (791 mg, 2.22 mmol) to the title compound. 60%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.14 (s, 1H), 8.75 (s, 4H), 7.80 (d, *J* = 7.7 Hz, 2H), 7.26 (d, *J* = 7.3 Hz, 2H), 3.29 (m, 4H), 2.60 (t, *J* = 7.4 Hz, 2H), 1.75 – 0.93 (m, 18H), 0.93 – 0.48 (m, 3H). ¹³C NMR (126 MHz, DMSO) δ 172.38, 167.98, 146.95, 131.22, 128.41, 128.34, 70.33, 70.04, 35.35, 33.07, 31.79, 31.17, 29.64, 29.07, 28.94, 26.11, 19.35, 18.40, 14.23. LCMS: *t*_R = 4.08; *m/z* = 374.3. HRMS *m/z* calc. for C₂₂H₃₆N₃O₂ (M+H), 374.2808; found, 374.2802.

11-(cyclohexylmethoxy)undecanoic acid (24)

General procedure C was used to couple cyclohexylmethanol and 11-bromoundecenoic acid (1.00 g, 3.77 mmol), with TBAB (121 mg, 0.38 mmol, 0.1 eq.) being added along with the 11-bromoundecenoic acid in one portion, to yield the title compound. 74%. Clear and colorless oil. *R*_f = 0.80 (60% EtOAc in hexanes; KMnO₄). ¹H NMR (500 MHz, CDCl₃) δ 6.46 (s, 1H), 3.30 (d, *J* = 6.6 Hz, 2H), 2.21 (t, *J* = 7.5 Hz, 2H), 1.72 – 0.95 (m, 27H), 0.93 – 0.65 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 177.87, 76.69, 71.00, 40.15, 34.00, 30.03, 29.52, 29.45, 29.36, 29.32, 29.18, 29.02, 26.52, 25.78, 24.73.

***N*-(1-cyanocyclopropyl)-11-(cyclohexylmethoxy)undecanamide (25)**

General procedure B was used to couple **24** (358 mg, 3.02 mmol) and 1-amino-1-cyclopropanecarbonitrile to yield the title compound. 81%. White solid. *R*_f = 0.51 (20% EtOAc in hexanes; Seebach's Dip). ¹H NMR (500 MHz, CDCl₃) δ 7.23 – 7.13 (m, 1H), 3.34 (t, *J* = 6.7 Hz, 2H), 3.16 (d, *J* = 6.6 Hz, 2H), 2.16 (t, *J* = 7.6 Hz, 2H), 1.78 – 0.99 (m, 31H), 0.86 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 174.62, 120.27, 76.79, 71.07, 37.95, 35.86, 30.12, 29.68, 29.49, 29.42, 29.37, 29.28, 29.14, 26.62, 26.11, 25.83, 25.28, 16.58.

***N*-(1-carbamimidoylcyclopropyl)-11-(cyclohexylmethoxy)undecanamide hydrochloride (26)**

General procedure A was used to convert **25** (791 mg, 2.22 mmol) to the title compound. 68%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.26 – 7.91 (m, 5H), 3.28 (t, *J* = 6.4 Hz, 2H), 3.10 (d, *J* = 6.4 Hz, 2H), 2.09 (t, *J* = 7.5 Hz, 2H), 1.72 – 0.64 (m, 33H). ¹³C NMR (126 MHz, DMSO) δ 174.53, 172.36, 76.19, 70.55, 37.96, 35.41, 32.38, 30.02, 29.63, 29.49, 29.44, 29.26, 29.12, 26.61, 26.15, 25.81, 24.92, 18.36. LCMS: *t*_R = 4.36; *m/z* = 380.3. HRMS *m/z* calc. for C₂₂H₄₂N₃O₂ (M+H), 380.3277; found, 380.3271.

1-aminocyclobutanecarbonitrile hydrochloride (31)

To a solution of cyclobutanone (930 mg, 1.0 eq.) in 2N NH₃/MeOH (0.2 M), was added potassium cyanide (2.0 eq.) and ammonium chloride (2.0 eq.). The reaction was run under ammonia gas (1 atm) at rt for 17 h. The reaction was then evaporated and the inorganic salts precipitated in CHCl₃ and removed via filtration through a fine frit. The solution was diluted in MeOH (100 mL), cooled to 0 °C, and treated with 12.1 N HCl (2.0 eq.). The reaction was let stir for 5 min and then evaporated to dryness to yield the title compound. 60%. White solid. ¹H NMR (300 MHz, CD₃OD) δ 2.73 – 2.47 (m, 2H), 2.29 (dt, *J* = 12.7, 8.8 Hz, 2H), 2.19 – 1.93 (m, 2H). ¹³C NMR (75 MHz, CD₃OD) δ 123.66, 37.44, 35.80, 15.47.

***N*-(1-cyanocyclobutyl)-4-dodecylbenzamide (32)**

General procedure L was used to couple **31** (87 mg, 0.90 mmol) and 4-dodecylbenzoyl chloride to yield the title compound. 30%. Clear and colorless oil. *R*_f = 0.48 (25% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 8.44 (d, *J* = 8.2 Hz, 2H), 7.99 (d, *J* = 8.7 Hz, 2H), 7.26 (s, 1H), 3.71 – 3.52 (m, 2H), 3.44 – 3.33 (m, 2H), 3.21 (dd, *J* = 21.0, 9.6 Hz, 2H), 3.11 – 2.78 (m, 2H), 2.35 (m, 2H), 2.16 – 1.91 (m, 18H), 1.62 (t, *J* = 6.6 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.71, 147.92, 130.05, 128.73, 127.21, 120.88, 48.00, 35.86, 34.14, 31.90, 31.16, 29.63, 29.56, 29.45, 29.34, 29.22, 22.68, 16.17, 14.13.

***N*-(1-carbamimidoylcyclobutyl)-4-dodecylbenzamide (33)**

General procedure A was used to convert **32** (100 mg, 0.27 mmol) to the title compound. 7%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.15 (s, 1H), 8.82 (s, 4H), 7.88 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 8.2 Hz, 2H), 2.68 – 2.56 (m, 4H), 2.42 (dd, *J* = 17.6, 11.1 Hz, 2H), 2.10 – 1.96 (m, 1H), 1.96 – 1.82 (m, 1H), 1.55 (pent., *J* = 6.8 Hz, 2H), 1.25 (m, 18H), 0.85 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (126 MHz, DMSO) δ 172.70, 166.46, 146.63, 130.64, 128.08, 127.95, 57.31, 34.98, 31.32, 31.01, 30.80, 29.03, 28.85, 28.73, 28.58, 22.12, 15.05, 13.99. LCMS: *t*_R = 5.29; *m/z* = 386.3. HRMS *m/z* calc. for C₂₄H₄₀N₃O (M+H), 386.3171; found, 386.3178.

(*S*)-*tert*-butyl 2-cyanopyrrolidine-1-carboxylate (34a)

To a solution of L-proline (600 mg, 5.21 mmol) in dioxane (7 mL) and 10% Na₂CO_{3(aq)} (14 mL) was added Boc₂O (2.0 eq.) at rt and let stir for 16 h. The reaction was washed 2x with hexanes (100 mL), then acidified with 1 N HCl (100 mL) and extracted 3x with EtOAc (200 mL). The EtOAc layer was dried with Na₂SO₄ and evaporated to a white solid. The crude white solid was then dissolved in CH₂Cl₂ (0.3 M) at 0°C and treated with TEA (3.0 eq.) then isobutyl chloroformate (1.1 eq.). The reaction turned turbid after the addition and was let warm to rt before slowly clearing over time. After 1 h at rt, the reaction was treated with 2 M NH₃ in MeOH (2.0 eq.) and let stir for 6 h. The reaction was evaporated to a white solid and taken on crude. The crude solid was dissolved in DMF (0.1 M) and 2,4,6-collidine (8 eq.) at 0°C and then treated with cyanuric chloride (3.15 eq.) and let warm to rt. The reaction was let stir for 12 h. The reaction was then extracted with EtOAc (20x the volume of DMF) and washed 3x with sat. NaHCO₃ (10x the volume of DMF), 3x with 1 N HCl (10x the volume of DMF), and once with brine (10x the volume of DMF). The organic layer was

then dried with Na₂SO₄, evaporated to a yellow oil, and immediately purified by flash chromatography to yield the title compound. 98%. Clear and colorless oil. R_f = 0.37 (20% EtOAc in hexanes; Ninhydrin). ¹H NMR (300 MHz, CDCl₃) δ 4.46 – 4.10 (m, 1H), 3.30 (dd, *J* = 13.9, 7.8 Hz, 1H), 3.16 (dd, *J* = 17.5, 8.1 Hz, 1H), 2.15 – 1.95 (m, 2H), 1.95 – 1.76 (m, 2H), 1.39 – 1.21 (m, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 153.01, 119.28, 81.08, 47.23, 45.79, 31.68, 30.84, 28.29, 24.73, 23.87.

(S)-1-(4-dodecylbenzoyl)pyrrolidine-2-carbonitrile (35a)

General procedure N was used to deprotect **34** (400 mg, 2.05 mmol). General procedure B was used to couple the deprotected **34** and 4-dodecylbenzoic acid to yield the title compound. 57%. White solid. R_f = 0.75 (40% EtOAc in hexanes; Seebach's Dip). ¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 7.6 Hz, 2H), 4.96 – 4.84 (m, 1H), 3.73 – 3.63 (m, 1H), 3.62 – 3.52 (m, 1H), 2.68 – 2.58 (m, 2H), 2.39 – 2.26 (m, 1H), 2.24 – 2.10 (m, 1H), 2.06 – 1.96 (m, 1H), 1.67 – 1.55 (m, 1H), 1.39 – 1.18 (m, 20H), 0.87 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 170.18, 146.28, 128.40, 127.61, 127.17, 118.73, 49.51, 46.87, 35.84, 31.91, 31.20, 30.30, 29.65, 29.56, 29.46, 29.34, 29.23, 25.58, 22.68, 14.12.

(S)-1-(4-dodecylbenzoyl)pyrrolidine-2-carboximidamide hydrochloride (36a)

General procedure A was used to convert **35a** (213 mg, 0.519 mmol) to the title compound. 64%. White solid. ¹H NMR (500 MHz, CD₃OD) δ 7.63 (d, *J* = 8.0 Hz, 2H), 7.30 (d, *J* = 8.0 Hz, 2H), 4.73 (t, *J* = 7.5 Hz, 1H), 3.87 (dd, *J* = 15.4, 9.0 Hz, 1H), 3.73 – 3.60 (m, 1H), 2.67 (t, *J* = 7.6 Hz, 2H), 2.54 (dd, *J* = 13.3, 6.6 Hz, 1H), 2.12 – 1.93 (m, 1H), 1.71 – 1.56 (m, 1H), 1.34 – 1.28 (m, 18H), 0.90 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CD₃OD) δ 171.79, 146.52, 131.91, 128.06, 127.63, 58.94, 50.59, 35.36, 31.66, 31.14, 31.03, 29.33, 29.28, 29.15, 29.06, 28.88, 25.27, 22.32, 13.03. LCMS: *t*_R = 5.04; *m/z* = 386.3. HRMS *m/z* calc. for C₂₄H₄₀N₃O (M+H), 386.3171; found, 386.3175.

(R)-1-(4-dodecylbenzoyl)pyrrolidine-2-carbonitrile (35b)

General procedure N was used to deprotect **ent-34a** (275 mg, 1.40 mmol). General procedure B was used to couple the deprotected **ent-34a** and 4-dodecylbenzoic acid to yield the title compound. 53%. White solid. R_f = 0.75 (40% EtOAc in hexanes; Seebach's Dip). ¹H and ¹³C NMR data were identical to that of **35a**.

(R)-1-(4-dodecylbenzoyl)pyrrolidine-2-carboximidamide hydrochloride (36b)

General procedure A was used to convert **35b** (213 mg, 0.519 mmol) to the title compound. 73%. White solid. ¹H and ¹³C NMR data were identical to that of **36a**.

(S)-1-(4-(7-(cyclohexylmethoxy)heptyl)benzoyl)pyrrolidine-2-carbonitrile (37)

General procedure N was used to deprotect **34** (179 mg, 0.911 mmol). General procedure B was used to couple the deprotected **34** and **21a** to yield the title compound. 61%. Clear and colorless oil. R_f = 0.38 (40% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 7.48 (d, *J* = 8.1 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 4.99 – 4.68 (m, 1H), 3.72 – 3.44 (m, 2H), 3.35 (t, *J* = 6.6 Hz, 2H), 3.16 (d, *J* = 6.6 Hz, 2H), 2.59 (t, *J* = 9.7 Hz, 2H), 2.42 – 1.90 (m, 4H), 1.57 (m, 10H), 1.40 – 1.01 (m, 9H), 1.01 – 0.72 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 170.19, 146.40, 133.46, 128.66, 127.79, 118.72, 77.05, 71.25, 58.68, 49.97, 38.24, 36.02, 31.33, 31.12, 30.37, 29.92, 29.50, 29.36, 26.88, 26.31, 26.10.

(S)-1-(4-(7-(cyclohexylmethoxy)heptyl)benzoyl)pyrrolidine-2-carboximidamide hydrochloride (38)

General procedure A was used to convert **37** (213 mg, 0.519 mmol) to the title compound. 85%. White solid. ¹H NMR (500 MHz, DMSO) δ 9.11 (s, 2H), 8.85 (s, 2H), 7.61 (d, *J* = 7.8 Hz, 2H), 7.25 (d, *J* = 7.7 Hz, 2H), 4.61 (t, *J* = 6.7 Hz, 1H), 3.81 (dd, *J* = 14.4, 7.4 Hz, 1H), 3.39 (m, 1H), 3.28 (t, *J* = 8.5, 2H), 3.09 (d, *J* = 6.5 Hz, 2H), 2.57 (m, 2H), 2.35 – 1.87 (m, 4H), 1.71 – 1.35 (m, 9H), 1.35 – 0.96 (m, 10H), 0.86 (m, 2H). ¹³C NMR (126 MHz, DMSO) δ 171.55, 169.93, 145.60, 133.21, 128.38, 128.30, 76.19, 70.53, 58.49, 50.66, 37.97, 35.39, 31.40, 31.13, 30.03, 29.59, 29.04, 26.62, 26.07, 25.81, 25.67. LCMS: *t*_R = 4.65; *m/z* = 428.3. HRMS *m/z* calc. for C₂₆H₄₂N₃O₂ (M+H), 428.3277; found, 428.3274.

(S)-1-(11-(cyclohexylmethoxy)undecanoyl)pyrrolidine-2-carbonitrile (39)

General procedure N was used to deprotect **34** (371 mg, 1.89 mmol). General procedure B was used to couple the deprotected **34** and **24** to yield the title compound. 84%. Clear and colorless oil. *R*_f = 0.29 (40% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 4.64 (d, *J* = 6.0 Hz, 1H), 3.53 (dd, *J* = 8.3, 7.1 Hz, 1H), 3.42 – 3.22 (m, 3H), 3.09 (d, *J* = 6.5 Hz, 2H), 2.44 – 1.84 (m, 6H), 1.78 – 1.35 (m, 6H), 1.35 – 0.96 (m, 19H), 0.81 (dd, *J* = 21.9, 10.6 Hz, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 172.23, 114.29, 77.45, 71.23, 46.51, 46.38, 38.19, 34.59, 30.31, 30.22, 29.89, 29.68, 29.55, 29.44, 26.83, 26.31, 26.05, 25.30, 24.56.

(S)-1-(11-(cyclohexylmethoxy)undecanoyl)pyrrolidine-2-carboximidamide hydrochloride (40)

General procedure A was used to convert **39** (433 mg, 1.15 mmol) to the title compound. 53%. White solid. ¹H NMR (500 MHz, DMSO) δ 8.89 (s, 4H), 4.45 (dd, *J* = 9.0, 4.0 Hz, 1H), 3.68 (ddd, *J* = 9.3, 7.2, 4.8 Hz, 1H), 3.41 (dd, *J* = 16.6, 7.3 Hz, 1H), 3.34 (s, 1H), 3.27 (t, *J* = 8.6 Hz, 2H), 3.09 (d, *J* = 8.5 Hz, 2H), 2.40 – 2.07 (m, 4H), 2.04 – 0.98 (m, 27H), 0.93 – 0.68 (m, 2H). ¹³C NMR (126 MHz, DMSO) δ 172.43, 171.78, 76.20, 70.56, 57.22, 47.31, 37.97, 33.86, 31.25, 30.03, 29.47, 29.39, 29.30, 29.23, 26.62, 25.81, 24.72, 24.22. LCMS: *t*_R = 4.51; *m/z* = 394.3. HRMS *m/z* calc. for C₂₃H₄₄N₃O₂ (M+H), 394.3434; found, 394.3425.

1-(3-(2-cyclohexylethyl)phenyl)ethanone (48)

To a 0.5 M solution of 9-BBN (1.5 eq.) was added vinylcyclohexane (1.5 mL, 11.3 mmol, 1.5 eq.) and let stir for 12 h. The reaction was then treated with 3N NaOH_(aq) (1.7 eq.), followed by the solid additions of 3-bromoacetophenone (1.00 mL, 7.56 mmol, 1.0 eq.) and Pd(PPh₃)₄ sequentially. The reaction was then heated to reflux for 1 h, then cooled to rt and extracted 2x into EtOAc (400 mL). The organic layer was then dried with Na₂SO₄, evaporated to a black oil, and immediately purified by flash chromatography to yield the title compound. 82%. Clear and colorless oil. *R*_f = 0.58 (10% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 7.85 – 7.58 (m, 2H), 7.42 – 7.07 (m, 2H), 2.59 (t, *J* = 7.3 Hz, 2H), 2.51 (s, 3H), 1.88 – 1.53 (m, 5H), 1.53 – 1.35 (m, 2H), 1.32 – 1.00 (m, 4H), 0.88 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 198.29, 143.87, 137.36, 133.36, 128.63, 128.19, 126.02, 39.53, 37.54, 33.46, 33.33, 26.85, 26.79, 26.52.

2-bromo-1-(3-(2-cyclohexylethyl)phenyl)ethanone (49)

To a solution of **48** (2.14 g, 9.28 mmol) in CHCl₃ (40 mL, 0.23 M) at 40°C was added Br₂ (1.0 eq.) dropwise. The reaction was complete immediately after the addition of the bromine, and was cooled to rt and quenched with sat. NaHCO₃ (100 mL). The mixture was then extracted 3x with CHCl₃ (100 mL). The organic layer was then dried with Na₂SO₄, evaporated to a black oil, and immediately purified by flash chromatography to yield the title compound. 92%. Yellow oil. *R*_f = 0.71 (10% EtOAc in hexanes; Seebach's Dip). ¹H

NMR (300 MHz, CDCl₃) δ 7.90 – 7.66 (m, 2H), 7.45 – 7.28 (m, 2H), 4.42 (s, 2H), 2.74 – 2.56 (m, 2H), 1.80 – 1.54 (m, 5H), 1.47 (dt, *J* = 10.4, 7.1 Hz, 2H), 1.32 – 1.01 (m, 4H), 0.89 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 191.54, 144.30, 134.30, 134.21, 129.04, 128.95, 126.56, 39.45, 37.51, 33.49, 33.32, 31.67, 26.89, 26.56.

4-(*tert*-butoxycarbonyl)benzoic acid

To a mixture of terephthalic acid (6.64 g, 40.0 mmol), Boc₂O (1.0 eq.), and DMAP (0.25 eq.) was added *t*BuOH (60 mL) and THF (20 mL) and heated to reflux for 24 h. The reaction was then evaporated to dryness and immediately purified by flash chromatography to yield the title compound. 36%. White solid. *R*_f = 0.50 (5% MeOH in CHCl₃; KMnO₄). Rotomer A: ¹H NMR (300 MHz, DMSO) δ 8.20 – 7.74 (m, 4H), 1.54 (s, 9H), 1.41 – 1.17 (m, 2H). Rotomer B: ¹H NMR (300 MHz, DMSO) δ 8.20 – 7.74 (m, 4H), 1.41 – 1.17 (m, 9H). Rotomer ratio A/B = 1.95.

tert-butyl (2-(3-(2-cyclohexylethyl)phenyl)-2-oxoethyl) terephthalate (50)

A solution of 4-(*tert*-butoxycarbonyl)benzoic acid (1.10 g, 4.95 mmol) and Cs₂CO₃ (0.51 eq.) in EtOH (80 mL, 0.06 M) was sonicated for 6 m at rt. The solvent was then evaporated and dried under vacuum for 20 min. The cesium carboxylate salt was then dissolved in DMF (30 mL) and **49** (1.2 eq.) was transferred by cannula in DMF (10 mL) at rt. The reaction was let stir for 12 h before being diluted with EtOAc (400 mL) and washed 3x with neat water (100 mL). The organic layer was then dried with Na₂SO₄, evaporated to a yellow oil, and immediately purified by flash chromatography to yield the title compound. 99%. Tan oil. *R*_f = 0.43 (10% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 8.11 (d, *J* = 6.8 Hz, 2H), 8.01 (d, *J* = 6.8 Hz, 2H), 7.73 (m, 2H), 7.47 – 7.04 (m, 2H), 5.55 (s, 2H), 2.62 (t, *J* = 6.9 Hz, 2H), 1.84 – 0.52 (m, 22H). ¹³C NMR (75 MHz, CDCl₃) δ 192.11, 165.50, 164.95, 144.34, 136.30, 134.28, 133.00, 129.95, 129.60, 128.98, 127.82, 125.37, 81.86, 67.01, 39.41, 37.49, 33.44, 33.30, 28.31, 26.83, 26.50.

tert-butyl 4-(4-(3-(2-cyclohexylethyl)phenyl)-1*H*-imidazol-2-yl)benzoate (51)

To a round bottom flask, fitted with a deans-stark trap containing 4 Å molecular sieves, was added **50** (1.00 g, 2.22 mmol) and ammonium acetate (5.0 eq.) and the mixture was dissolved in xylenes (30 mL, 0.07 M). The reaction was then heated to reflux for 7 h. The reaction was then cooled to rt, evaporated to a black oil, and immediately purified by flash chromatography to yield the title compound. 36%. Yellow solid. *R*_f = 0.05 (10% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 8.00 (d, *J* = 8.4 Hz, 2H), 87.92 (d, *J* = 8.4 Hz, 2H), 7.62 (s, 1H), 7.52 (d, *J* = 7.7 Hz, 1H), 7.42 (s, 1H), 7.32 – 7.15 (m, 1H), 7.05 (d, *J* = 7.6 Hz, 1H), 2.70 – 2.39 (m, 2H), 1.85 – 1.01 (m, 20H), 1.01 – 0.69 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 165.90, 146.77, 144.07, 134.13, 131.60, 130.22, 128.88, 127.64, 125.44, 122.74, 81.65, 39.61, 37.65, 33.56, 33.48, 28.42, 26.91, 26.56.

(*S*)-1-(4-(4-(3-(2-cyclohexylethyl)phenyl)-1*H*-imidazol-2-yl)benzoyl)pyrrolidine-2-carbonitrile (52)

General procedure N was used to deprotect the *t*Bu ester on compound **51** (193 mg, 0.448 mmol) to yield the corresponding carboxylic acid. In a separate flask, general procedure N was used to deprotect **34** (88 mg, 0.448 mmol). General procedure B was used to couple the deprotected **51** and **34** to yield the title compound. 84%. Yellow solid. *R*_f = 0.57 (EtOAc; Seebach's Dip). ¹H NMR (300 MHz, DMSO) δ 12.81 (s, 1H), 8.22 – 7.90 (m, 2H), 7.90 – 7.34 (m, 5H), 7.26 (t, *J* = 6.8 Hz, 1H), 7.03 (d, *J* = 6.5 Hz, 1H), 4.88 (dd, *J* = 7.5, 5.2 Hz, 1H), 4.09 (ddd, *J* = 12.3, 7.6, 3.3 Hz, 1H), 3.98 – 3.40 (m, 3H), 3.08 – 2.66 (m, 2H), 2.66 – 2.51 (m, 2H), 2.39 – 0.56 (m, 13H). ¹³C NMR (75 MHz, DMSO) δ 168.98, 145.55, 143.45,

142.40, 134.95, 133.13, 129.09, 128.77, 128.44, 125.29, 124.94, 122.55, 120.15, 115.64, 49.93, 47.44, 39.89, 37.49, 33.45, 31.92, 30.28, 26.89, 26.52, 25.84.

(S)-1-(4-(4-(3-(2-cyclohexylethyl)phenyl)-1H-imidazol-2-yl)benzoyl)pyrrolidine-2-carboximidamide hydrochloride (53)

General procedure A was used to convert **52** (140 mg, 0.310 mmol) to the title compound. 81%. Yellow solid. ¹H NMR (500 MHz, DMSO) δ 12.85 (s, 1H), 9.07 (s, 2H), 8.74 (s, 2H), 8.07 (d, *J* = 8.2 Hz, 2H), 7.80 (d, *J* = 8.2 Hz, 2H), 7.65 (m, 2H), 7.25 (t, *J* = 7.6 Hz, 1H), 7.03 (d, *J* = 7.2 Hz, 1H), 4.62 (t, *J* = 7.5 Hz, 1H), 3.93 – 3.70 (m, 1H), 3.47 (dd, *J* = 19.6, 12.3 Hz, 1H), 2.67 – 2.53 (m, 2H), 2.37 (dd, *J* = 14.8, 8.7 Hz, 1H), 2.02 – 0.92 (m, 14H). ¹³C NMR (126 MHz, DMSO) δ 171.36, 169.60, 145.32, 143.20, 142.05, 134.89, 134.67, 132.81, 129.15, 128.91, 126.78, 124.71, 122.30, 120.07, 58.61, 50.66, 39.71, 37.25, 33.22, 31.42, 26.64, 26.28, 25.93. LCMS: *t*_R = 3.79; *m/z* = 470.3. HRMS *m/z* calc. for C₂₉H₃₆N₅O (M+H), 470.2920; found, 470.2916.

4-(4-(3-(2-cyclohexylethyl)phenyl)oxazol-2-yl)benzoic acid (54)

To a round bottom flask containing **50** (1.10 g, 2.44 mmol) and ammonium acetate (5.0 eq.) was added AcOH (20 mL, 0.12 M). The reaction was then heated to reflux for 16 h. The reaction was then cooled to rt, evaporated to dryness, and immediately purified by flash chromatography to yield the title compound. 25%. Yellow solid. *R*_f = 0.58 (EtOAc; Seebach's Dip). Compound was crude by NMR and taken on to the next step without further purification.

(S)-1-(4-(4-(3-(2-cyclohexylethyl)phenyl)oxazol-2-yl)benzoyl)pyrrolidine-2-carbonitrile (55)

General procedure N was used to deprotect **34** (88 mg, 0.448 mmol). General procedure B was used to couple the deprotected **34** and crude **54** to yield the title compound. 81%. Yellow solid. *R*_f = 0.51 (50% EtOAc in hexanes; Seebach's Dip). ¹H NMR (300 MHz, CDCl₃) δ 8.15 (d, *J* = 8.0 Hz, 2H), 7.96 (s, 1H), 7.81 – 7.52 (m, 4H), 7.30 (dt, *J* = 6.6, 4.9 Hz, 1H), 7.14 (d, *J* = 7.6 Hz, 1H), 5.03 – 4.69 (m, 1H), 3.91 – 3.26 (m, 2H), 2.77 – 2.43 (m, 2H), 2.43 – 0.62 (m, 17H). ¹³C NMR (75 MHz, CDCl₃) δ 169.25, 160.94, 144.13, 142.74, 136.60, 134.30, 130.90, 129.79, 128.93, 128.65, 128.28, 126.69, 125.81, 123.13, 118.81, 49.69, 47.18, 39.68, 37.67, 33.54, 30.48, 26.92, 26.57, 25.82.

(S)-1-(4-(4-(3-(2-cyclohexylethyl)phenyl)oxazol-2-yl)benzoyl)pyrrolidine-2-carboximidamide hydrochloride (56)

General procedure A was used to convert **55** (169 mg, 0.373 mmol) to the title compound. 75%. Yellow solid. ¹H NMR (500 MHz, DMSO) δ 9.23 (s, 2H), 9.03 (s, 2H), 8.78 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 2H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.73 – 7.60 (m, 2H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.16 (d, *J* = 7.6 Hz, 1H), 4.67 (t, *J* = 7.5 Hz, 1H), 3.99 – 3.69 (m, 1H), 3.50 – 3.37 (m, 1H), 2.61 (t, *J* = 9.1 Hz, 2H), 2.44 – 2.30 (m, 1H), 2.01 – 1.79 (m, 3H), 1.74 (d, *J* = 13.0 Hz, 2H), 1.69 – 1.54 (m, 3H), 1.54 – 1.41 (m, 2H), 1.30 – 1.00 (m, 4H), 1.00 – 0.75 (m, 2H). ¹³C NMR (126 MHz, DMSO) δ 171.39, 169.19, 160.68, 143.73, 141.87, 137.70, 136.51, 130.93, 129.22, 129.15, 128.68, 126.16, 125.49, 123.13, 58.50, 50.57, 37.24, 33.18, 33.02, 31.46, 26.62, 26.25, 25.61. LCMS: *t*_R = 4.79; *m/z* = 471.3. HRMS *m/z* calc. for C₂₉H₃₅N₄O₂ (M +H), 471.2760; found, 471.2759.

tert-butyl 4-carbamothioylbenzoate (57)

4-(*tert*-butoxycarbonyl)benzoic acid (3.24 g, 14.6 mmol) was then dissolved in CH₂Cl₂ (0.3 M) at 0°C and treated with TEA (3.0 eq.) then isobutyl chloroformate (1.1 eq.). The reaction turned turbid after the addition and was let warm to rt before slowly clearing over time. After 1 h at rt, the reaction was treated with 2 N NH₃ in MeOH (2.0 eq.) and let stir for 6 h.

The reaction was evaporated to a white solid and purified by flash chromatography to yield the corresponding amide. 66%. White solid. $R_f = 0.39$ (60% EtOAc in hexanes; UV). ^1H NMR (300 MHz, CDCl_3) δ 8.02 (d, $J = 8.1$ Hz, 2H), 7.84 (d, $J = 8.1$ Hz, 2H), 6.48 (s, 2H), 1.59 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3) δ 169.25, 165.10, 137.02, 135.22, 129.87, 127.47, 81.99, 28.35. The amide was then dissolved in THF (0.5 M) and treated with Lawesson's reagent (0.6 eq.) in one portion. The reaction was let stir for 3 h before being evaporated to dryness and purified by flash chromatography to yield the title compound. 92%. Yellow/green solid. $R_f = 0.93$ (50% EtOAc in hexanes; Seebach's Dip). ^1H NMR (500 MHz, DMSO) δ 10.06 (s, 1H), 9.65 (s, 1H), 8.12 – 7.55 (m, 4H), 1.53 (s, 9H). ^{13}C NMR (126 MHz, DMSO) δ 199.69, 164.80, 143.60, 133.51, 129.12, 127.88, 81.62, 28.18.

tert-butyl 4-(4-(3-(2-cyclohexylethyl)phenyl)thiazol-2-yl)benzoate (58)

To a solution of **57** (1.95 g, 8.22 mmol) and KHCO_3 (1.1 eq.) in THF (45 mL) at -5°C was added **49** (2.05 g, 6.63 mmol) in THF (5 mL) and let warm to rt. The reaction was let stir for 2 h and then cooled to -5°C again and treated with TEA (2.2 eq.) and TFAA (1.1 eq.). The reaction was let warm to rt and stir for 16 h. The reaction was diluted with CHCl_3 (400 mL) and quenched with water (100 mL). The organic layer was then dried with Na_2SO_4 , evaporated to dryness, and immediately purified by flash chromatography to yield the title compound. 80%. Yellow solid. $R_f = 0.88$ (10% EtOAc in hexanes; Seebach's Dip). ^1H NMR (300 MHz, CDCl_3) δ 8.18 – 7.95 (m, 4H), 7.84 (s, 1H), 7.81 – 7.64 (m, 1H), 7.45 (s, 1H), 7.33 (t, $J = 7.6$ Hz, 1H), 7.17 (d, $J = 7.6$ Hz, 1H), 2.67 (t, $J = 8.6$ Hz, 2H), 1.94 – 1.44 (m, 15H), 1.44 – 1.06 (m, 5H), 0.96 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 166.61, 165.35, 157.22, 143.99, 137.37, 135.15, 134.43, 133.24, 130.52, 128.94, 126.92, 126.47, 124.04, 113.70, 81.48, 77.68, 39.74, 37.70, 33.60, 33.48, 28.43, 26.99, 26.65.

(S)-1-(4-(4-(3-(2-cyclohexylethyl)phenyl)thiazol-2-yl)benzoyl)pyrrolidine-2-carbonitrile (59)

General procedure N was used to deprotect the tBu ester on compound **58** (2.10 mg, 4.69 mmol) to yield the corresponding carboxylic acid. In a separate flask, general procedure N was used to deprotect **34** (919 mg, 4.69 mmol). General procedure B was used to couple the deprotected **58** and **34** to yield the title compound. 65%. Yellow solid. $R_f = 0.36$ (50% EtOAc in hexanes; Seebach's Dip). ^1H NMR (300 MHz, CDCl_3) δ 8.02 (d, $J = 8.1$ Hz, 2H), 7.79 (s, 1H), 7.73 (d, $J = 7.8$ Hz, 1H), 7.65 (d, $J = 7.5$ Hz, 2H), 7.48 (s, 1H), 7.30 (t, $J = 7.6$ Hz, 1H), 7.14 (d, $J = 7.7$ Hz, 1H), 4.82 (s, 1H), 3.85 – 3.35 (m, 2H), 2.64 (t, $J = 5.3$ Hz, 2H), 2.40 – 1.81 (m, 4H), 1.81 – 1.39 (m, 7H), 1.39 – 1.02 (m, 4H), 1.02 – 0.74 (m, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 169.21, 168.71, 166.42, 157.05, 144.05, 136.02, 134.33, 128.95, 128.71, 128.51, 126.69, 123.97, 118.92, 113.77, 49.74, 47.23, 39.72, 37.64, 33.55, 33.43, 30.42, 26.93, 26.59, 25.83.

(S)-1-(4-(4-(3-(2-cyclohexylethyl)phenyl)thiazol-2-yl)benzoyl)pyrrolidine-2-carboximidamide hydrochloride (60)

General procedure A was used to convert **59** (682 mg, 1.50 mmol) to the title compound. 74%. White solid. ^1H NMR (500 MHz, DMSO) δ 9.23 (s, 2H), 9.02 (s, 2H), 8.23 (s, 1H), 8.15 – 8.00 (m, 2H), 7.94 – 7.60 (m, 4H), 7.37 (t, $J = 6.5$ Hz, 1H), 7.17 (d, $J = 6.4$ Hz, 1H), 4.66 (s, 1H), 3.84 (dd, $J = 34.3, 15.3$ Hz, 1H), 3.53 – 3.20 (m, 2H), 2.62 (t, $J = 5.6$ Hz, 2H), 2.53 – 2.09 (m, 2H), 2.08 – 1.31 (m, 9H), 1.31 – 0.96 (m, 4H), 0.89 (m, 2H). ^{13}C NMR (126 MHz, CDCl_3) δ 176.16, 173.99, 171.05, 160.83, 148.44, 142.06, 139.74, 138.98, 133.98, 133.47, 131.24, 131.00, 128.82, 124.56, 120.56, 63.26, 55.32, 41.95, 37.93, 37.79, 36.20, 31.37, 31.00, 30.38. LCMS: $t_R = 5.08$; $m/z = 487.3$. HRMS m/z calc. for $\text{C}_{29}\text{H}_{35}\text{N}_4\text{OS}$ (M + H), 487.2532; found, 487.2530.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by grants from the National Institutes of Health (R01 GM067958 to KRL and TLM). The authors thank Jose L. Tomsig, Department of Pharmacology, University of Virginia, for S1P/LCMS quantification. AJK would like to offer special thanks to the Jefferson Scholars Foundation for financial support.

Abbreviations List

| | |
|--------------|--|
| 9-BBN | 9-borabicyclo[3.3.1]nonane |
| AcOH | acetic acid |
| DGK | diacylglycerol kinase |
| DMF | dimethyl formamide |
| DMS | dimethyl sphingosine |
| EGF | epidermal growth factor |
| HDAC | histone deacetylase |
| LPA | lysophosphatidic acid |
| MOE | molecular operating environment |
| PDGF | platelet derived growth factor |
| PFK | phosphofructokinase |
| PKC | protein kinase C |
| PyBOP | benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate |
| S1P | sphingosine 1-phosphate |
| S1PR | sphingosine 1-phosphate receptor |
| SAR | structure activity relationship |
| SphK | sphingosine kinase |
| VEGF | vascular endothelial growth factor |

References

1. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. *Nat Rev Cancer*. 2010; 10:489–503. [PubMed: 20555359]
2. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting sphk1 as a new strategy against cancer. *Curr Drug Targets*. 2008; 9:662–673. [PubMed: 18691013]
3. Spiegel S, Milstien S. Sphingosine-1-phosphate: An enigmatic signalling lipid. *Nat Rev Mol Cell Biol*. 2003; 4:397–407. [PubMed: 12728273]
4. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. *Nat Rev Cancer*. 2004; 4:604–616. [PubMed: 15286740]
5. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: Lessons from sphingolipids. *Nat Rev Mol Cell Biol*. 2008; 9:139–150. [PubMed: 18216770]
6. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. *Annu Rev Biochem*. 2009; 78:743–768. [PubMed: 19231986]

7. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. *Science*. 2009; 325:1254–1257. [PubMed: 19729656]
8. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. *Clin Cancer Res*. 2008; 14:6996–7003. [PubMed: 18980995]
9. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. *J Neuropathol Exp Neurol*. 2005; 64:695–705. [PubMed: 16106218]
10. Dyrskjøt L, Krühøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K, Ørntoft TF. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. *Cancer Res*. 2004; 64:4040–4048. [PubMed: 15173019]
11. Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. *Breast cancer research and treatment*. 2008; 112:41–52. [PubMed: 18058224]
12. Erez-Roman R, Pienik R, Futerman AH. Increased ceramide synthase 2 and 6 mRNA levels in breast cancer tissues and correlation with sphingosine kinase expression. *Biochem Biophys Res Commun*. 2010; 391:219–223. [PubMed: 19912991]
13. Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, Ai Y, Ristimaki AP, Fyrst H, Sano H, Rosenberg D, Saba JD, Proia RL, Hla T. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. *Mol Cell Biol*. 2006; 26:7211–7223. [PubMed: 16980623]
14. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, Hannun YA, Obeid LM. Role for sphingosine kinase 1 in colon carcinogenesis. *FASEB J*. 2009; 23:405–414. [PubMed: 18824518]
15. Li W, Yu CP, Xia J-t, Zhang L, Weng GX, Zheng H-q, Kong Q-l, Hu L-j, Zeng MS, Zeng Y-x, Li M, Li J, Song LB. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. *Clin Cancer Res*. 2009; 15:1393–1399. [PubMed: 19228740]
16. Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP, Ahlquist P. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. *Cancer Res*. 2007; 67:4605–4619. [PubMed: 17510386]
17. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. *Cancer Res*. 2004; 64:55–63. [PubMed: 14729608]
18. Andersson A, Ritz C, Lindgren D, Edén P, Lassen C, Heldrup J, Olofsson T, Råde J, Fontes M, Porwit-Macdonald A, Behrendtz M, Höglund M, Johansson B, Fioretos T. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: Prediction of leukemic and genetic subtype as well as of minimal residual disease status. *Leukemia*. 2007; 21:1198–1203. [PubMed: 17410184]
19. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, Yun JK. Sphingosine kinase 1 protein and mRNA are overexpressed in non-hodgkin lymphomas and are attractive targets for novel pharmacological interventions. *Leuk Lymphoma*. 2008; 49:948–954. [PubMed: 18452097]
20. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y. High expression of sphingosine kinase 1 and s1p receptors in chemotherapy-resistant prostate cancer pc3 cells and their camptothecin-induced up-regulation. *Biochem Biophys Res Commun*. 2006; 342:1284–1290. [PubMed: 16516161]
21. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. *Cancer Res*. 2005; 65:11667–11675. [PubMed: 16357178]

22. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. *Clin Cancer Res*. 2005; 11:7234–7242. [PubMed: 16243793]
23. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Sterry W, Stockfleth E. Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. *Mol Cancer*. 2006; 5:30. [PubMed: 16893473]
24. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, D'Andrea RJ, Vadas MA. An oncogenic role of sphingosine kinase. *Curr Biol*. 2000; 10:1527–1530. [PubMed: 11114522]
25. Vadas M, Xia P, McCaughan G, Gamble J. The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction? *Biochim Biophys Acta*. 2008; 1781:442–447. [PubMed: 18638570]
26. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. *Trends Endocrinol Metab*. 2007; 18:300–307. [PubMed: 17904858]
27. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, Vadas MA, Xia P. Estrogen transactivates egfr via the sphingosine 1-phosphate receptor edg-3: The role of sphingosine kinase-1. *J Cell Biol*. 2006; 173:301–310. [PubMed: 16636149]
28. Döll F, Pfeilschifter J, Huwiler A. Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line mcf7 and triggers enhanced proliferation and migration. *Endocr Relat Cancer*. 2007; 14:325–335. [PubMed: 17639048]
29. Shida D, Fang X, Kordula T, Takabe K, Lépine S, Alvarez SE, Milstien S, Spiegel S. Cross-talk between lpa1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. *Cancer Res*. 2008; 68:6569–6577. [PubMed: 18701480]
30. Ahmad M, Long JS, Pyne NJ, Pyne S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. *Prostaglandins Other Lipid Mediat*. 2006; 79:278–286. [PubMed: 16647641]
31. Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. *J Biol Chem*. 2006; 281:8518–8527. [PubMed: 16415355]
32. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. *Mol Cancer Ther*. 2009; 8:809–820. [PubMed: 19372554]
33. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in k562 human chronic myeloid leukemia cells. *J Biol Chem*. 2007; 282:10922–10934. [PubMed: 17303574]
34. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature*. 1996; 381:800–803. [PubMed: 8657285]
35. Pitson SM, Moretti PAB, Zebol JR, Lynn HE, Xia P, Vadas MA, Wattenberg BW. Activation of sphingosine kinase 1 by erk1/2-mediated phosphorylation. *EMBO J*. 2003; 22:5491–5500. [PubMed: 14532121]
36. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH, Milstien S, Spiegel S. Sphk1 and sphk2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. *J Biol Chem*. 2005; 280:37118–37129. [PubMed: 16118219]
37. Sankala HM, Hait NC, Paugh SW, Shida D, Lépine S, Elmore LW, Dent P, Milstien S, Spiegel S. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. *Cancer Res*. 2007; 67:10466–10474. [PubMed: 17974990]
38. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, Milstien S, Spiegel S. Sphingosine kinase type 2 is a putative bh3-only protein that induces apoptosis. *J Biol Chem*. 2003; 278:40330–40336. [PubMed: 12835323]
39. Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S. Cell membrane signaling as target in cancer therapy: Inhibitory effect of n,n-dimethyl and n,n,n-trimethyl sphingosine derivatives on in vitro

- and in vivo growth of human tumor cells in nude mice. *Cancer Res.* 1991; 51:1613–1618. [PubMed: 1998952]
40. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. *Blood.* 2008; 112:1382–1391. [PubMed: 18511810]
 41. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD. Pharmacology and antitumor activity of abc294640, a selective inhibitor of sphingosine kinase-2. *J Pharmacol Exp Ther.* 2010; 333:129–139. [PubMed: 20061445]
 42. Wong L, Tan SSL, Lam Y, Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. *J Med Chem.* 2009; 52:3618–3626. [PubMed: 19469544]
 43. Xiang Y, Hirth B, Kane JL, Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C, Booker M. Discovery of novel sphingosine kinase-1 inhibitors. Part 2 *Bioorg Med Chem Lett.* 2010; 20:4550–4554.
 44. Xiang Y, Asmussen G, Booker M, Hirth B, Kane JL, Liao J, Noson KD, Yee C. Discovery of novel sphingosine kinase 1 inhibitors. *Bioorg Med Chem Lett.* 2009; 19:6119–6121. [PubMed: 19800228]
 45. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. *Cancer Res.* 2003; 63:5962–5969. [PubMed: 14522923]
 46. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S, Spiegel S. Targeting sphingosine kinase 1 inhibits akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. *Cancer Res.* 2009; 69:6915–6923. [PubMed: 19723667]
 47. Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD. Efficacy of a novel sphingosine kinase inhibitor in experimental crohn's disease. *Inflammopharmacology.* 2010; 18:73–85. [PubMed: 20151210]
 48. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, Upson JJ, Smith CD. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. *Dig Dis Sci.* 2008; 53:997–1012. [PubMed: 18058233]
 49. Puneet P, Yap CT, Wong L, Lam Y, Koh DR, Mochhala S, Pfeilschifter J, Huwiler A, Melendez AJ. Sphk1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. *Science.* 2010; 328:1290–1294. [PubMed: 20522778]
 50. Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M, Morris AJ, Wamhoff BR, Lynch KR, Macdonald TL. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. *J Med Chem.* 2010; 53:2766–2778. [PubMed: 20205392]
 51. Miller DJ, Jerga A, Rock CO, White SW. Analysis of the staphylococcus aureus dgkb structure reveals a common catalytic mechanism for the soluble diacylglycerol kinases. *Structure.* 2008; 16:1036–1046. [PubMed: 18611377]
 52. Kharel Y, Mathews TP, Kennedy AJ, Houck JD, Lynch KR. A rapid assay for assessment of sphingosine kinase inhibitors and substrates. *Anal Biochem.* 2011; 411:230–235. [PubMed: 21216217]
 53. Schaefer F, Petters G. Base-catalyzed reaction of nitriles with alcohols. A convenient route to imidates and amidine salts *The Journal of Organic Chemistry.* 1961; 26:412–418.
 54. Wildman S, Crippen G. Prediction of physicochemical parameters by atomic contributions. *Journal of chemical information and computer sciences.* 1999; 39:868–873.
 55. Kohn M, Breinbauer R. The staudinger ligation - a gift to chemical biology. *Angew Chem Int Edit.* 2004; 43:3106–3116.
 56. Bal B, Childers W, Pinnick H. Oxidation of alpha, beta-unsaturated aldehydes. *Tetrahedron.* 1981; 37:2091–2096.
 57. Nichols CE, Lamb HK, Lockyer M, Charles IG, Pyne S, Hawkins AR, Stammers DK. Characterization of salmonella typhimurium yege, a putative lipid kinase homologous to

- eukaryotic sphingosine and diacylglycerol kinases. *Proteins*. 2007; 68:13–25. [PubMed: 17393457]
58. Bakali HMA, Herman MD, Johnson KA, Kelly AA, Wieslander A, Hallberg BM, Nordlund P. Crystal structure of yegs, a homologue to the mammalian diacylglycerol kinases, reveals a novel regulatory metal binding site. *J Biol Chem*. 2007; 282:19644–19652. [PubMed: 17351295]
59. Cabrera R, Baez M, Pereira HM, Caniuguir A, Garratt RC, Babul J. The crystal complex of phosphofructokinase-2 of *Escherichia coli* with fructose-6-phosphate: Kinetic and structural analysis of the allosteric ATP inhibition. *Journal of Biological Chemistry*. 2011; 286:5774–5783. [PubMed: 21147773]
60. Martinez-Oyanedel J, McNae IW, Nowicki MW, Keillor JW, Michels PAM, Fothergill-Gilmore LA, Walkinshaw MD. The first crystal structure of phosphofructokinase from a eukaryote: *Trypanosoma brucei*. *J Mol Biol*. 2007; 366:1185–1198. [PubMed: 17207816]
61. Blake JD, Cohen FE. Pairwise sequence alignment below the twilight zone. *J Mol Biol*. 2001; 307:721–735. [PubMed: 11254392]
62. Merrill AH, Stokes TH, Momin A, Park H, Portz BJ, Kelly S, Wang E, Sullards MC, Wang MD. Sphingolipidomics: A valuable tool for understanding the roles of sphingolipids in biology and disease. *J Lipid Res*. 2009; 50 (Suppl):S97–102. [PubMed: 19029065]




Figure 1. Comparison between tail length and potency for the amide orientations in compounds **1** and **2**. Compound **1** derivatives shown in red. Compound **2** derivatives shown in blue. SphK1 inhibition shown as solid lines. SphK2 inhibition shown as dotted lines.




Figure 2. SphK homology model. (A) Crystal structure DGKB. (δ -helices = teal, β -sheets = lavender, ATP = yellow stick model, and Mg^{2+} = white sphere) (B) SphK1 homolog. (C) Theoretical binding orientation of compound 38 with ATP and protein backbone. (D) 2D representation of the amidine in compound 38 chelating ATP.




Figure 3.
Generic Scaffold for the Linker Design Proof of Principle.




Figure 4. Progression of linker design. (A) Theoretical binding orientation of compound **38** chelating ATP (both drawn as stick models). (B) Deletion of aliphatic linker between the aryl amide and cyclohexyl group in **38**. (C) Generation of a new linker (**56**) with a reduced number of rotatable bonds.







Figure 5. S1P concentrations in human leukemia U937 cells dosed with SphK inhibitors. Error bars indicate 95% confidence limits. Concentrations are indicated by shading and patterns.




Scheme 1.
The Sphingosine Rheostat.




Scheme 2.
Outline of inhibitor optimization.

**Scheme 3.**


Example synthesis of an aryl deleted tail modification.




Scheme 4.
Example synthesis of an ether tail modification.




Scheme 5.
Example synthesis of a non-ether tail modification.

**Scheme 6.**


Example synthesis of ether containing/aryl deletion tail modified compounds.




Scheme 7.
Synthesis of **23a**.




Scheme 8.
Synthesis of **26**.




Scheme 9.
Synthesis of the alpha, alpha-cyclobutyl head group analog **33**.




Scheme 10.
Synthesis of the proline-based rigid analog **36a**.




Scheme 11.
Combination of tail and head group modifications.



Scheme 12.
Synthesis of imidazole **53**.






Scheme 13.
Synthesis of oxazole **56**.



Scheme 14.
Synthesis of thiazole **60**.

Table 1


Previously described amidine-based sphingosine kinase inhibitors.

| Compound | Structure | K_I (μM) ^a | | |
|----------|---|--------------------------------------|-------|--------------------------------|
| | | SphK1 | SphK2 | SphK1 Selectivity ^b |
| VPC94075 |  | 55 | 20 | 0.7 |
| 1 |  | 0.2 | 0.5 | 5 |
| 2 |  | 0.3 | 6 | 40 |


^a $K_I = [I]/(K_i/K_M - 1)$; K_M of Sphingosine at SphK1 = 10 μM ; K_M of Sphingosine at SphK2 = 5 μM

^b Selectivity = $(K_I/K_M)^{\text{SphK2}} / (K_I/K_M)^{\text{SphK1}}$

Table 2

K_I values for the tail modified compounds.

| Compound | Tail Group (R) | K _I (μM) ^a | | |
|----------|----------------|----------------------------------|-------|--------------------------------|
| | | SphK1 | SphK2 | SphK1 Selectivity ^b |
| 2 | | 0.3 | 6 | 40 |
| 4a | | 6 | 7.5 | 2.5 |
| 4b | | 5.4 | >100 | >37 |
| 4c | | 9 | >100 | >22 |
| 9a | | 5 | 38 | 15 |
| 14a | | 0.50 | >10 | >40 |
| 14b | | 1.3 | >10 | 15 |
| 9b | | 0.39 | 12 | 61 |
| 9c | | 0.24 | 7 | 58 |
| 9d | | 0.80 | >20 | >50 |
| 9e | | 1.5 | 4.6 | 6.1 |









| Compound | Tail Group (R) | K_I (μM) ^a | | |
|------------|----------------|--------------------------------------|-------|--------------------------------|
| | | SphK1 | SphK2 | SphK1 Selectivity ^b |
| 19a | | 0.11 | 26 | 470 |
| 19b | | 0.45 | 25 | 110 |

^a $K_I = [I]/(K_M/K_M - 1)$; K_M of Sphingosine at SphK1 = 10 μM ; K_M of Sphingosine at SphK2 = 5 μM

^b Selectivity = $(K_I/K_M)^{\text{SphK2}} / (K_I/K_M)^{\text{SphK1}}$

Table 3

K_I values for alternate amide configurations.







| Compound | Structure | K_I (μM) ^a | | SphK1 Selectivity ^b |
|------------|---|--------------------------------------|-------|--------------------------------|
| | | SphK1 | SphK2 | |
| 1 |  | 0.2 | 0.5 | 5 |
| 23a |  | 0.13 | 15 | 240 |
| 23b |  | 0.17 | 18 | 210 |
| 23c |  | 1.3 | 40 | 62 |
| 30 |  | 4.0 | 10 | 5 |
| 26 |  | 0.095 | 12 | 250 |

^a $K_I = [I]/(K' M/KM - 1)$; KM of Sphingosine at SphK1 = 10 μM ; KM of Sphingosine at SphK2 = 5 μM

^b Selectivity = $(K_I/KM)^{\text{SphK2}} / (K_I/KM)^{\text{SphK1}}$

Table 4

K_I values for head group modifications.

| Compound | Structure | K _I (μM) ^a | | SphK1 Selectivity ^b | |
|----------|---|----------------------------------|-------|--------------------------------|-------|
| | | SphK1 | SphK2 | SphK1 | SphK2 |
| 1 |  | 0.2 | 0.5 | 5 | |
| 33 |  | 1.6 | 5 | 6.3 | |
| 36a |  | 0.13 | 1.5 | 24 | |
| 36b |  | 16 | 5 | 0.6 | |
| 38 |  | 0.075 | 3 | 80 | |
| 47 |  | 0.099 | 5.3 | 110 | |





| Compound | Structure | K_I (μM) ^a | | |
|----------|-----------|--------------------------------------|-------|--------------------------------|
| | | SphK1 | SphK2 | SphK1 Selectivity ^b |
| 40 | | 0.13 | 8 | 130 |

^a $K_I = [I]/(K_M/K_M - 1)$; K_M of Sphingosine at SphK1 = 10 μM ; K_M of Sphingosine at SphK2 = 5 μM

^b Selectivity = $(K_I/K_M)^{\text{SphK2}} / (K_I/K_M)^{\text{SphK1}}$

Table 5

K_I values for the heterocycle linker series.







| Compound | Structure | Predicted SphK1 | K_I (μM) ^a | | SphK1 | SphK2 | SphK1 Selectivity ^b |
|----------|--|-----------------|--------------------------------------|-------------|-------|-------|--------------------------------|
| | | | Lower Limit | Upper Limit | | | |
| 38 |  | - | - | - | 0.075 | 3.0 | 80 |
| 53 |  | 0.065 | 0.01 | 0.45 | 2.0 | 20 | 20 |
| 56 |  | 0.031 | 0.005 | 0.21 | 0.047 | 4.2 | 180 |
| 60 |  | 0.035 | 0.006 | 0.24 | 0.11 | 6.0 | 110 |

^a $K_I = [I]/(K' M/KM - 1)$; KM of Sphingosine at SphK1 = 10 μM ; KM of Sphingosine at SphK2 = 5 μM

^b Selectivity = $(K_I/KM) \text{SphK2}/(K_I/KM) \text{SphK1}$

Table 6

K_I values for inhibitors used for SIP inhibition in living U937 cells.

| Compound | Structure | K_I (μM) ^d | | SphK1 Selectivity ^b |
|----------|---|--------------------------------------|-------|--------------------------------|
| | | SphK1 | SphK2 | |
| 1 |  | 0.2 | 0.5 | 5 |
| 19a |  | 0.111 | 26 | 470 |
| 38 |  | 0.075 | 3.0 | 80 |
| 56 |  | 0.047 | 4.2 | 180 |
| 9ab |  | 1.4 | 31 | 44 |
| SKI-II |  | 12 | 33 | 6 |

^d $K_I = [I]/(K' - [K])$; K_M of Sphingosine at SphK1 = 10 μM ; K_M of Sphingosine at SphK2 = 5 μM

$$b_{\text{Selectivity}} = (K_I/K_M)^{\text{SphK2}} / ((K_I/K_M)^{\text{SphK1}})$$